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ABSTRACT OF DISSERTATION

EFFECT OF COMBINATION EXPOSURE TO ZIDOVUDINE AND
SULFAMETHOXAZOLE-TRIMETHOPRIM ON IMMUNE RESPONSE IN MICE AND
HUMANS
The drug-drug interaction involving zidovudine and sulfamethoxazole-trimethoprim
was investigated using an in vitro culture system, an in vivo mouse model, and a clinical
trial in HIV-infected patients. We hypothesized that combination exposure causes
immune cell populations in the bone marrow to undergo apoptotic cell death, and that
the toxicity would affect the host response to an infectious stimulus.
Mice were dosed with zidovudine, sulfamethoxazole-trimethoprim, the combination
of both drugs, or vehicle only control via oral gavage. Focusing on B-lineage cells in the
bone marrow, we determined that cells of the rapidly cycling, early pre-B cell subset are
targeted, as well as pro-B cells earlier in development. This toxicity was found to be cell
cycle dependent, with an increase in percentage of cells in the S/G2/M phases of the
cycle. In vitro experiments using the drugs in a bone marrow culture system
demonstrated that the effect of cytotoxicity with combination exposure is synergistic and
concentration-dependent. The mechanism of apoptosis that is induced appears to be
caspase-independent.
To measure host response in mice, animals treated with zidovudine plus
sulfamethoxazole-trimethoprim were infected with Pneumocystis murina pneumonia,
and the group that received the combination of agents had a blunted antigen-specific
IgG response, possibly due to a decreased number of B cells and activated B cells in
the draining lymph nodes of the lungs.
A clinical trial was conducted in HIV-infected patients, dividing subjects into groups
receiving zidovudine, sulfamethoxazole-trimethoprim, the combination of both, or
neither agent. Upon vaccination with the influenza vaccine, the combination treatment
group had a blunted humoral response, with reduced antigen-specific serum IgG titers
as compared to the control group. We conclude that the drug-drug interaction involving
zidovudine and sulfamethoxazole-trimethoprim is clinically-significant, and clinicians
must consider this toxicity when treating patients with these agents concurrently.

KEYWORDS: zidovudine, sulfamethoxazole-trimethoprim, apoptosis, B lymphocytes,
humoral immunity
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CHAPTER 1. Introduction

A. OVERVIEW
Patients infected with human immunodeficiency virus (HIV) undergo worsening of
immunosuppression over the course of their illness. While this is mainly a direct result
of the virus, iatrogenic causes can be contributory. Two common agents used in the
treatment of this patient population include zidovudine (ZDV) and sulfamethoxazoletrimethoprim (SMX-TMP). Investigators recently reported that these agents have an
additive toxic effect on immune cell populations in the spleen and peripheral blood (1).
The purpose of this dissertation was to investigate the mechanism of this combined
toxicity in mice, and to evaluate its impact on host response in both mice and humans.
With the ever-increasing number of agents on the market worldwide, drug-drug
interactions continue to be a significant cause of morbidity and mortality among all
patient populations, accounting for as much as 3-28% of hospital admissions (2, 3).
Adverse drug reactions occur in 5-20% of hospitalized patients, many caused by drugdrug interactions (4, 5). Patients infected with HIV are at a high risk of developing drugdrug interactions due to the large number of agents used to treat them. The
medications required to treat HIV-infected patients include antiretroviral drugs
comprising highly active antiretroviral therapy (HAART), anti-infectives used for
prophylaxis and treatment of opportunistic infections (OI), adjunct treatments for
additional disease states, or additional agents to treat iatrogenic toxicities that many of
these drugs can cause. Many drug-drug interactions that are typical of patients with
acquired immunodeficiency syndrome (AIDS) have been well described and reviewed
(6). Iatrogenic effects associated with these agents have the potential to adversely
affect clinical outcomes among patients infected with HIV.
Advances in the treatment of HIV infection have increased patient survival and
decreased morbidity and mortality so significantly that the disease is now considered to
be a chronic condition. With the availability of more effective antiretroviral regimens,
researchers and clinicians have prolonged the time interval during which viral replication

1

is controlled and therefore effective immune function is maintained, prohibiting OI and
other complications from HIV infection. HAART benefits these patients by decreasing
viral replication of HIV. As a result, these patients are maintained long-term on
treatment with a multitude of agents.
However, HAART therapy can also cause a variety of adverse effects that can
impact morbidity and quality of life. Bone marrow suppression is associated with the
use of many antiretrovirals, with the highest incidence associated with ZDV. It is
important for clinicians treating HIV to understand the effects of these agents on the
immune system. Further immunosuppression from drug therapy could adversely
influence the outcome of HIV treatment and enhance patient susceptibility to OI and
malignancy. This work will investigate the hypothesis that ZDV used in combination
with SMX-TMP, another agent commonly used in patients infected with HIV, causes
clinically-significant alterations to immune function that could contribute to impaired host
defense. By way of introduction, aspects of host defense in response to HIV infection
will be presented. This will be followed by a discussion of the impact that HIV-infection
has on immune cell populations and their functions, including an overview of apoptosis
and its role in HIV disease. Drug therapy will then be applied to this overview, and the
positive and negative aspects of treatment will be presented. The focus will then turn
toward ZDV and SMX-TMP, and the hypothesis that these drugs, when used in
combination, adversely affect B cell development in the bone marrow, thus leading to
significant immunologic impairment.

B. IMMUNE RESPONSE AND HIV INFECTION
HIV disease is characterized by CD4+ T lymphocyte depletion (7). As the CD4+ cell
population declines, it leaves the host susceptible to OI which, along with the patient’s
CD4+ cell count, defines disease progression toward AIDS. CD4+ cells die via direct
cytopathologic effects of the virus, as well as by apoptosis induction due to exposure to
viral antigens (8-11). This leads to decreased immune surveillance, and increased
incidence of OI and neoplasms.
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Primary immune response to HIV is both humoral and cell-mediated. After
dissemination of the virus to lymphoid organs and throughout the body, the immune
response controls the burst of viral replication. The virus is incompletely eliminated and
goes into a state of persistent replication. This characteristic is unique to HIV and is not
found among other human viral pathogens (12). During this phase, HIV becomes
trapped in germinal centers of the lymph nodes. CD4+ T cells migrate here as part of
their normal response to infection, where they then become infected with the virus. It is
paradoxical that the very immune response which controls viral spread also effectively
propagates the disease. The immune system subsequently remains in an activated
state for an extended period (12).

Cellular immune response to HIV infection
The immune system controls the virus to extend the infected host’s survival by
employing CD8+ T cells upon initial infection. There is an increase in the number of
HIV-specific CD8+ cytotoxic T lymphocytes (CTL) that inhibit viral replication by
destroying virally-infected cells (13). In addition to these activities, CD8+ cells also
release anti-HIV macromolecules that combat the virus, including the chemokines
RANTES (regulated on activation, normal T cell expressed and secreted), MIP-1α
(macrophage inflammatory protein-1α), and MIP-1β (14). These chemokines inhibit
infection of activated CD4+ T cells by HIV by inhibiting chemoattractant cytokine
receptor type 5 (CCR5), one of the several seven-transmembrane G-protein coupled
chemokine coreceptors utilized by the virus for cell entry (15-17). CD8+ T cell
populations remain constant, keeping the patient in a clinical phase of latency for
extended time periods.
Over time the CD8+ cell population will decline allowing the virus to increase
replication, with resultant declines in CD4+ cell numbers. There is a strong correlation
between a decline in HIV-specific CTL activity and progression of the disease (18, 19).
This eventually leads to uncontrolled viral replication and lymph node destruction in
progressive illness (20). Additionally, CD4+ T cells respond to HIV epitopes presented
in the context of MHC class II (21). This causes CD4+ cells to secrete interleukin (IL)-2
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which, while helpful to aid cytotoxic responses, has also been shown to increase HIV
replication (22).
In addition to death due to direct infection of the virus, cytotoxicity in CD4+ T cells
also occurs by indirect means. Infected cells can bind to uninfected CD4+ cells and
deplete them (10). This occurs because the molecular events associated with the
fusion of the HIV viral envelope and the cell membrane that occur during infection can
also occur when an infected CD4+ cell expressing viral envelope proteins comes into
contact with an uninfected T cell. This causes a “syncytium” of cells to form, thereby
depleting them (23). Another mechanism of indirect depletion occurs when uninfected
CD4+ cells that express HIV proteins on their surface are killed by CTL responses in an
“innocent bystander” phenomenon (24, 25). The CD4 receptor will cross-link soluble
viral proteins such as gp120 that, in the absence of TCR activation, induces apoptosis
(26).
Impaired hematopoiesis can also lead to depletion in CD4+ cell numbers due to
decreases in production. Some CD34+ lymphoid progenitors in the bone marrow
express CD4, and are therefore susceptible to the virus (27, 28). HIV infection also
increases Fas expression on CD34+ cells which increases apoptosis in these
progenitors (29). Fas is a “death receptor” through which cells are stimulated to
undergo programmed cell death. These mechanisms will be discussed below.
Finally, HIV infection can prime CD4+ T cells for apoptosis. T cells from HIV patients
undergo higher rates of apoptosis when compared to T cells from normal individuals
(30, 31). Infected cells are sensitized to undergo apoptosis if CD4 receptors have been
cross-linked to the HIV envelope glycoprotein gp120, followed by T cell receptor ligation
(30, 31). Because activation of these cells triggers apoptosis, as T cells respond to an
infectious stimulus they are depleted (26). This occurs through the intrinsic
mitochondrial pathway of apoptosis, although the details remain unknown (32). The
percentage of apoptotic CD4+ and CD8+ T cells in lymph node sections is three to four
times higher in HIV-infected patients than in normal individuals (11).
In addition to loss of absolute cell numbers, HIV can also influence CD4+ T cell
function through decreased production of IL-2 and decreased expression of the IL-2
receptor (33). This, in addition to the decreased expression of CD40 ligand discussed
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below, can decrease the functionality of the remaining CD4+ T cells in HIV-infected
patients.

Humoral immunity in HIV infection
Several types of antibodies are produced in response to HIV disease. Beginning
with primary infection, antibodies to the viral core protein p24 develop, which decreases
viremia in the early stages of infection (34). The eventual decline in response to p24
antigen correlates to disease progression in later stages of illness (35, 36). Other
antibodies can be present that neutralize HIV that are viral isolate-specific, most often
targeting the HIV envelope protein gp120 (37, 38). Some of these antibodies inhibit the
interactions between HIV and CCR5, which prevents the entry of the virus into the CD4+
cell (39). Other antibodies can neutralize a wide range of viral isolates, and the
presence of these more broadly-specific antibodies correlates with slower disease
progression (35, 40, 41). Despite the positive effects of neutralizing antibodies against
HIV, it has also been demonstrated that some antibodies present in HIV-infected
individuals can actually enhance replication of HIV in vitro (42, 43).
HIV infection severely damages the humoral immune response which incurs
phenotypic and functional alterations. HIV infection results in increased proportions of B
cells with an activated phenotype, resulting in a hyper-production of gammaglobulin
(IgG) (44, 45). Despite having elevated IgG levels, HIV-infected individuals have an
impaired ability to produce specific antibodies in response to neo-antigens (46-50). The
decrease in antigen-specific IgG titers in HIV-infected individuals has been positively
correlated with CD4+ T cell count, and inversely correlated to viral load (51).
B cells in patients infected with HIV do not upregulate CD70 normally after being
stimulated by activated T cells, which impairs CD70-dependent immunoglobulin
synthesis (52). The interaction which up-regulates CD70 expression, between CD40 on
B cells and CD40L on T cells, is also affected by a decrease in CD40L expression on T
cells in HIV-positive patients, meaning that the defect in antigen-specific Ig production is
also a result of CD4+ T cell dysfunction (52). Additionally investigators have shown that
memory B cells (CD27+) are depleted from the blood of HIV-infected individuals,
possibly due to persistent T cell activation (53). In clinical trials examining B cell
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responses in AIDS patients, it is unknown if drug therapy plays a role in B cell
malfunction, since this issue has not been studied (46-50).
Dysfunction of the humoral immune system leads to the inability of the patient to
properly control extracellular pathogens (54). These include extracellular bacteria,
parasites, and fungi, such as Streptococcus pneumoniae and Pneumocystis (54-56).
Although the rate increases as CD4+ count decreases, bacteria are still the most likely
cause of pneumonia in an HIV-infected patient with a high CD4+ cell count, with
pneumococcus being the most likely cause in this subset of patients (57). This example
illustrates the impact of B cell dysregulation on host defense in HIV disease.

Apoptosis
Apoptosis is an important mechanism of homeostasis in adult tissues by the
activation of a controlled cellular self-destruction program. This occurs for the removal
of infected, transformed, or damaged cells that can be induced by a variety of stimuli,
including death receptor ligation, the absence of growth and survival factors, starvation,
DNA damage, viral infection, anticancer drugs, and ultraviolet radiation (58). Apoptotic
cells have a distinct morphology which includes membrane blebbing, exposure of
phosphatidylserine to the outside of the plasma membrane, nuclear fragmentation, and
chromatin condensation (59, 60). Cells ultimately lyse and are fragmented into
apoptotic bodies, which are engulfed by macrophages without causing an inflammatory
response (61, 62). As mentioned above, apoptosis plays an important role in HIVinfection.
Cell death is divided into two main types: programmed cell death, during which the
cell plays an active role in its demise, and passive death (necrosis). Apoptosis occurs
as a result of a host of stimuli, and it proceeds through a small number of distinct
pathways (58). The two major signaling cascades utilize a family of cysteine proteases
called caspases, a group of highly-regulated enzymes that undergo cleavage and
activation during apoptosis (63-65). The extrinsic cascade originates from the activation
of cell membrane death receptors resulting in caspase activation, and the intrinsic
pathway involves mitochondrial release of pro-apoptotic factors to activate caspases to
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induce apoptosis (66). Additionally, apoptosis can occur in a caspase-independent
manner (discussed in Chapter 6) (67, 68).
The extrinsic pathway originates from the ligation of death receptors on the cell
surface, including Fas (CD95), TNF-related apoptosis-inducing ligand receptors (TRAILR), and TNF-receptor 1 (TNF-R1) (69, 70). Fas ligand (FasL) is expressed by CTL and
some activated CD4+ T cells. They recognize cells to be terminated through antigen
presentation in the context of MHC. The TRAIL-receptors function in maintaining
immune system homeostasis, so that activated cells can be deleted in a form of
regulation (71). These receptors have death domains that trimerize upon ligation,
thereby recruiting Fas-associated death domain protein (FADD) or TNF-R-associated
death domain protein (TRADD). Pro-caspase-8 is then recruited and activated, which in
turn activates caspase-3, the main effector caspase through which both pathways flow,
which signals the cell to undergo apoptosis (72, 73).
The intrinsic pathway centers on the mitochondria. Different stressors including
ultraviolet radiation, growth factor withdrawal, and drug exposure can cause the release
of cytochrome c from the mitochondria via complex mechanism of regulation, governed
by proteins in the Bcl-2 family. This family contains anti-apoptotic (Bcl-2, Bcl-XL) and
pro-apoptotic (Bax, Bid) members that exert their affect on the mitochondria by
preventing or inducing mitochondrial dysfunction (74, 75). These proteins are under the
control of p53 gene transcription (76). Increases in cytochrome c release can also be
induced through the extrinsic pathway with a “crosstalk” signal utilizing caspase-2 (77).
Cytochrome c then activates caspase-9, which in turn activates the effector caspases
through caspase-3, causing apoptosis (78). CTL can also induce apoptosis through
granzyme B secretion, which directly activates caspase-3 (75). The mitochondria can
also be stimulated to release apoptosis-inducing factor (AIF), which is a caspaseindependent pathway that can also lead to apoptosis (see Chapter 6 for details).
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C. DRUG TREATMENT: THE GOOD AND THE BAD

Efficacy of HAART
HAART controls viral replication in infected patients, thereby increasing CD4+ T cell
counts and improving patient survival (79-81). HAART targets a variety of viral
processes to decrease the impact of mutations that result in resistance to therapy.
Many investigations have shown that the number and function of CD4+ cells increases
in response to successful viral load reduction with HAART (82-85). In one example, a
study involving 44 HIV-positive patients, Lederman et. al. found that CD4+ cells’
proliferative capability and delayed-type hypersensitivity reaction potential were both
improved after 12 weeks of treatment with a combination of ZDV, lamivudine, and
ritonavir (83). Similarly, HAART not only decreases direct viral attack on CD4+ cells, but
also restores T cell proliferation, as Lu et. al. demonstrated in CD4+ and CD8+ T cells in
vivo and in vitro in 99 adults infected with HIV (86). Investigators in this study treated
patients with combination therapy for one year, and enhanced ability of T cells to
survive in vitro was associated with the use of the protease inhibitors (PI) indinavir and
ritonavir (86). As a consequence of these effects, the addition of PI to HAART allows
for a more effective defense against opportunistic pathogens such as cytomegalovirus
(CMV), Pneumocystis jirovecii, and Candida albicans, resulting in a decrease in patient
mortality (82, 87-89).
Antiretroviral therapy has many positive effects on the bone marrow of infected
individuals. Bone marrow progenitor cells are adversely affected by HIV causing
impaired hematopoiesis. CD34+ progenitor cells in the bone marrow of patients infected
with HIV typically have an increase in Fas and Fas ligand expression, and an
overproduction of tumor necrosis factor-α (TNF-α), an inflammatory cytokine that can
increase toxicity to bone marrow progenitor CD34+ cells (29, 90). HIV infection thereby
increases the apoptosis rate of CD34+ progenitor cells in the bone marrow. Isgro et. al.
demonstrated that HAART reduces this destruction by decreasing Fas expression on
the surface of these progenitors (90). This group showed this using in vitro culture of
bone marrow aspirates from HIV-infected patients pre- and post-HAART (90). The
expression of TNF-α was also decreased as a result of HAART in bone marrow cells
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from HIV patients cultured ex vivo (90). This effect was postulated by the investigators
to be due to the presence of PI (90).
Sloand et. al. demonstrated that these agents can also decrease apoptosis rates and
caspase-1 content in CD4+ cells (91). Caspase-1, also known as interleukin-1βconverting enzyme, is a cell signaling protein in CD4+ T cells that is preferentially
expressed in cells of HIV-infected patients (91). Caspase-1 mediates apoptosis in
these cells, and when inhibited reduces activation-induced cell death (92). This group
demonstrated that the addition of ritonavir to cultured bone marrow cells from HIVinfected subjects increased colony formation and decreased apoptosis in CD34+ cells,
and that this effect was blocked by the addition of a caspase-1 inhibitor (93). These
studies highlight the ability of PI to directly affect cells in the bone marrow.
An additional benefit of HAART and subsequent virologic control is the decreased
incidence of AIDS-associated neoplasms. Clinicians use HAART therapy to decrease
the occurrence of Kaposi’s sarcoma and non-Hodgkin’s lymphoma (94, 95). HAART
restores immune surveillance which leads to a decrease in incidence of OI and cells
that have undergone oncogenic transformation.

Toxicity of HAART
Bone marrow suppression in this patient population can be caused by a variety of
insults. In addition to direct viral effects, iatrogenic suppression from HIV therapy,
neoplasms, malnutrition, and OI (including cytomegalovirus, Mycobacterium avium
complex (MAC), and histoplasmosis) can adversely affect bone marrow cell survival and
replication (96). Anemia, thrombocytopenia, lymphopenia, and neutropenia are found in
most AIDS patients. Bone marrow in patients with AIDS displays a host of pathologic
processes, including lymphocyte infiltration, dysplasia, reticulin fibrosis, granulomatous
myelitis, and plasmacytosis (97, 98). HIV-infected patients with advanced disease also
have high incidences of the aforementioned neoplasms, particularly Kaposi’s sarcoma
and non-Hodgkin’s lymphoma, hypothesized to be due in part to a decrease in immune
surveillance (99). Although many of these maladies are directly associated with the
virus, drug regimens also have significant adverse effects on immune functions.
Investigators have studied and characterized these adverse effects associated with
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drug therapy via in vitro, animal, and human studies. Clinicians must also be aware of
the potential toxicities associated with the use of these agents.
ZDV is associated with the most potent myelosuppressive effects among available
antiretrovirals (100, 101). The reported clinical incidence of bone marrow toxicities
associated with ZDV, including anemia, neutropenia, and granulocytopenia, ranges
from 2 to 45% (102-105). Increases in the mean corpuscular volume of red blood cells
is a hallmark of ZDV therapy, its incidence so reliable that it has been shown to be a
valuable marker for HAART adherence (103, 106). Several groups have shown that
ZDV affects lymphocytes in their early stages of development in the bone marrow (107109). The triphosphorylated form of ZDV is the active form of the drug. However, the
monophosphorylated form is responsible for its toxicity by inhibiting thymidylate kinase
and lowering intracellular thymidine pools (107). This toxicity is associated with an
inhibition of hematopoietic progenitors in murine and human bone marrow (108-110).
This is likely due to the fact that these progenitors tend to be more actively cycling than
are mature lymphocytes.
Nucleoside reverse transcriptase inhibitors (NRTI), especially ZDV, induce apoptosis
in immune cell populations of HIV-infected patients (111, 112). Viora et. al. found
inhibited cell cycle progression and increased apoptosis in human peripheral blood
mononuclear cells exposed to clinically relevant concentrations of ZDV and
dideoxycytidine (ddC) in vitro (111). Several groups have demonstrated ZDV-induced
mitochondrial dysfunction in hematological cells because of the drug’s affinity for
mitochondrial DNA polymerase gamma (113-116). Other investigators have shown that
ZDV makes cells more susceptible to apoptosis by inducing mitochondrial membrane
hyperpolarization (112, 117). Additionally, investigators have shown didanosine to
cause mitochondrial toxicity in human cell lines (113). Clinical studies examining other
cell types have demonstrated that these agents cause mitochondrial toxicity in HIVpositive patients, which is then associated with an increased incidence of
hyperlactatemia and lipodystrophy (116, 118). The clinical manifestations of NRTIinduced mitochondrial toxicity resemble those of inherited mitochondrial diseases,
including lactic acidosis, myopathy, nephrotoxicity, peripheral neuropathy, and
pancreatitis (119).
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Conversely, PI prevent ZDV-induced apoptosis (93, 120-122). In a study by
Matarrese et. al., apoptosis induced by various stimuli in activated T cells cultured from
the peripheral blood of HIV-infected patients was decreased through an increase in
mitochondrial membrane potential by saquinavir, lopinavir, and indinavir (120).
Interestingly, one of the agents used to induce apoptosis was ZDV (120). The addition
of PI in this study decreased lymphocyte apoptosis by influencing mitochondrial
homeostasis. Apoptosis in cultured T lymphocytes obtained from HIV-infected subjects
in another study decreased with the addition of nelfinavir to combination antiretroviral
therapy (122). This mechanism is postulated to be due to activated lymphocytes having
hyperpolarized mitochondrial membranes, which make the cells prone to apoptosis. PI
are able to stabilize the mitochondria in these cells. Therefore, with combination
therapy, the addition of a PI could be beneficial not only to decrease viral replication and
mutation, but also through this direct affect on lymphocyte apoptosis.
ZDV also causes a decrease in T cell responses to antigens, as well as a depletion
of T cell populations in the thymus in mice (123). CD4+CD8+ (double-positive) cell
numbers in the thymus were decreased as a result of ZDV exposure after mice were
dosed via oral gavage for a period of 14 days. However, T cell populations in the
peripheral blood of these animals were unaffected. At higher doses (1000 mg/kg/day),
thymus atrophy occurred. When cultured from treated animals, T cell proliferation to
antigenic stimuli was decreased significantly (123). IL-2 exposure reversed the effects
that ZDV had on T cell populations and on their function in this investigation (123). In
another study, Gallicchio et. al showed that IL-1 activity decreased the toxicity of ZDV
on murine hematopoietic cells in vitro (124). These studies conclude that the
mechanism of toxicity to T lymphocyte development could be due to inhibition of
cytokine production. Investigators have used IL-2 successfully in clinical trials to
increase lymphoproliferation in HIV patients, lending further support to this notion (125,
126).
Several other reverse transcriptase inhibitors adversely affect the bone marrow.
Zalcitabine-associated neutropenia has been reported in up to 17% of patients in clinical
trials (127-129). Didanosine, lamivudine, and delavirdine also cause neutropenia, but
incidence rates are less than 10% (129-132). The incidence of granulocytopenia
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associated with delavirdine increased from 16% to 63% with ZDV co-administration in a
phase I/II trial involving 85 patients (132). PI suppress the bone marrow as well,
although at a much lower incidence and severity than ZDV. Indinavir causes
neutropenia in rare cases, and is associated with an anemia rate of less than 2% (133,
134). Saquinavir and nelfinavir cause mild dose-related neutropenia in clinical studies,
however this is typically not clinically significant (135-137).

Anti-infectives and immunosuppression
Medications commonly used for prophylaxis and treatment of OI in HIV-infected
patients can also have adverse effects on bone marrow. Foscarnet is used to treat
CMV retinitis and herpes simplex virus in HIV positive patients. Use of this antiviral
agent can cause anemia, leucopenia, granulocytopenia, and thrombocytopenia (138,
139). However, it is associated with a much lower incidence of severe, dose-limiting
leucopenia than ganciclovir, another agent that is used in this patient population to treat
CMV. Foscarnet can be given safely to patients with HIV, as demonstrated in a clinical
study of ten patients with newly diagnosed CMV retinitis who received induction and
maintenance therapy (140). Additionally, cidofovir causes neutropenia in as many as
20% of patients using the drug for CMV retinitis (141). Much of the toxicity associated
with these agents is due to their use in combination with ZDV, which is discussed in the
subsequent section.
Agents that affect folic acid synthesis such as dapsone, trimetrexate, pyrimethamine,
and SMX-TMP are used in HIV-infected patients for the treatment and prophylaxis of
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis. These agents also cause
bone marrow toxicity and may contribute to immunosuppression in this patient
population. Dapsone is often used in the prophylaxis of PCP in patients with AIDS who
are unable to tolerate SMX-TMP. Severe hematologic effects reported with dapsone
use include agranulocytosis, aplastic anemia, and hemolytic anemia at estimated
incidences of less than 1% (142-144). Trimetrexate, another agent used in the
treatment of moderate to severe PCP, causes a high rate of myelosuppression (145,
146). Sattler et. al. reported that 46% of 25 patients receiving various doses of
trimetrexate (ranging from 45 to 90 mg/m2) in combination with folinic acid
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(Leucovorin®) experienced dose-modifying hematologic toxicity (146). Pyrimethamine
can also be used in the treatment and prevention of toxoplasmosis and Pneumocystis in
AIDS patients, and is associated with causing megaloblastic anemia, leucopenia, and
thrombocytopenia (147, 148). Folinic acid is often dosed with pyrimethamine in order to
decrease these effects. Clinicians must be aware of the bone marrow toxicity
associated with the use of these agents, and exercise caution when combining these
drugs and ZDV, which can have additive toxicities.
SMX-TMP, the drug of choice for the prophylaxis and treatment of PCP, is
particularly problematic with regards to bone marrow suppression. A higher than
normal incidence of adverse reactions is associated with the use of SMX-TMP in
patients with AIDS (149-151). SMX-TMP treatment-limiting adverse events occur in 6080% of HIV-infected patients, whereas that rate is approximately 15% in non-HIV
infected individuals (149, 150). The toxicities of this combination, based on in vitro data,
are attributable to the oxidative metabolites of SMX (152). Patients with HIV infection
have depleted intracellular glutathione (GSH) concentrations, a molecule utilized by
cells as a reducing agent for the detoxification of oxidative species (153, 154). GSH is
responsible for the conversion of toxic SMX metabolites back to the parent compound,
which is then metabolized to non-toxic species and eliminated (155, 156). Investigators
have linked this depletion of GSH by the virus to SMX-TMP intolerance in HIV-infected
patients (153, 154). This will be discussed in detail in Chapter 4.

Antiretroviral drug-drug interactions and bone marrow toxicity
When treating patients infected with HIV, clinicians should take caution in
considering potential drug-drug interactions that could adversely affect immune function,
particularly interactions involving ZDV. Combining ZDV with agents that affect its
metabolism can lead to increased toxicity. Fluconazole, atovaquone, and methadone
all interfere with the clearance of ZDV (157-159). Fluconazole increased the area under
the concentration versus time curve (AUC) by 74% after 7 days of dosing in a
randomized, crossover study of 12 men infected with HIV (157). In an open-label,
randomized, crossover study of 14 patients examining concurrent atovaquone therapy,
the AUC of ZDV was increased by 31% (160). Additionally, probenecid, which is
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typically administered with cidofovir to prevent nephrotoxicity, can decrease the renal
clearance of ZDV (161, 162). Clinicians should consider these drug combinations when
investigating causes of hematologic toxicity in patients who are HIV positive.
Caution must also be taken when prescribing PI, as they have the ability to inhibit
cytochrome P450 (CYP) liver enzymes that are responsible for the metabolism of many
drugs (163, 164). Ritonavir is the most potent inhibitor, but other PI, including
saquinavir, indinavir, and nelfinavir will also inhibit CYP3A4 to a clinically significant
degree. This inhibition has the potential to increase the exposure to drugs metabolized
by this isoenzyme, which could lead to bone marrow suppression if used with agents
that cause this type of toxicity. Additionally, the non-nucleoside reverse transcriptase
inhibitor (NNRTI) delavirdine inhibits CYP3A4, and can increase the concentrations and
risk of toxicity of the PI (164).
Drugs used in combination with antiretrovirals can also increase hematologic toxicity,
independent of pharmacokinetic interactions. These interactions are presumed to be
due to additive or synergistic bone marrow toxicity, but the precise mechanisms of the
combined toxicities of most of these combinations remain unstudied. Investigators have
defined several interactions associated with combination therapy with ZDV that are
independent of systemic pharmacokinetic mechanisms. These studies are summarized
in Table 1.1. Little is known about the clinical impact of co-treatment with antiretrovirals
along with these other medications.
The use of ZDV with ganciclovir caused an incidence of severe to life-threatening
hematologic toxicity in 82% of patients in a phase I, multicenter study of 41 patients with
AIDS-related CMV infection (165). The conclusions of this study confirmed that patients
receiving ganciclovir usually cannot tolerate the full recommended dose of ZDV
(600mg/day) (165). In a retrospective study of 32 patients with AIDS, combining
didanosine with ganciclovir was much better tolerated than combining ZDV with
ganciclovir (166). Nine percent of patients given didanosine plus ganciclovir in this
study developed dose-limiting hematologic toxicity versus 28% of patients in the ZDV
plus ganciclovir group (166).
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Table 1.1 Summary of ZDV drug-drug interaction literature.
Interactions with concomitant exposure with ZDV that are independent of systemic
pharmacokinetic mechanisms.
Drug
Ganciclovir

Effect
Leucopenia,
granulocytopenia

Study Type
Clinical

Refs
165, 166,
167

Comment
Severe, must
decrease AZT
dose or
discontinue

Foscarnet

Leucopenia,
granulocytopenia

Clinical

138, 139,
140, 168

Much lower
incidence/
severity than
ganciclovir

Dapsone

Decrease T cell ex
vivo proliferation
Hematologic
toxicity

Mouse, ex vivo

168

Clinical

170

10% incidence

Clarithromycin

Neutropenia,
lymphopenia

Mouse

169

Decrease splenic
cellularity

TMP/SMX

Decrease B cells/
macrophages in
spleen

Mouse

1

Protease
inhibitors

Decrease AZTinduced apoptosis
in T cells

Human, ex vivo

120, 121

Stabilize
mitochondrial
membrane
hyperpolarization

In a clinical trial comparing the safety and efficacy of foscarnet versus ganciclovir for
the treatment of CMV retinitis in patients with AIDS, subjects receiving foscarnet had a
mortality rate of 36% as compared to 51% in the patients receiving ganciclovir (167).
Subjects receiving ZDV had the drug held in the ganciclovir treatment group during the
initial phase of therapy, and then reinstated at a lower dose thereafter (300mg/day).
Even with this alteration in antiretroviral therapy, the relative risk of neutropenia (1.88)
was higher in the patients receiving ganciclovir compared to foscarnet (167).
In animal models, ZDV used in combination with dapsone, clarithromycin, or
TMP/SMX causes hematopoietic toxicity due to additive effects (1, 168, 169). In a study
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by Freund et. al., concurrent administration of ZDV and dapsone increased the severity
of ZDV-induced macrocytic anemia in normal mice (168). The investigators also
demonstrated a decrease in proliferation when T cells were taken from mice treated
with the drug combination and stimulated ex vivo (168). In a clinical study comparing
safety and efficacy of dapsone to pentamidine in HIV-infected patients on ZDV, 6 out of
50 patients receiving dapsone experienced significant hematologic toxicity (170).
Dapsone should be utilized with caution in patients receiving ZDV.
Administration of ZDV with clarithromycin is also of concern. Combination dosing in
normal mice for 28 days resulted in severe hematotoxicity, with a significant decrease in
neutrophil and lymphocyte populations in the peripheral blood, as well as a reduction in
splenic cellularity of 67% (169). Although the mechanism for this augmentation of
toxicity is unknown, the authors cited the ability of clarithromycin to inhibit cytokine
production in several cell types (169, 171-173). While clarithromycin is clinically
effective in the treatment of MAC (174, 175), it has also been associated with a possible
increased mortality rate in HIV-infected patients (175, 176). This group randomly
assigned patients with MAC bacteremia to receive twice-daily clarithromycin at doses of
500mg, 1000mg, and 2000mg for 12 weeks (175). For each group, mycobacteremia
decreased during the 12 weeks. Unfortunately, treatment-limiting toxicity caused by
clarithromycin occurred in 20% to 40% of patients, and patients receiving the higher
doses of clarithromycin had higher death rates than did those treated with the 500-mg
dose (175).

ZDV in combination with SMX-TMP
It is common for patients infected with HIV to be treated simultaneously with ZDV
and SMX-TMP. However, the impact of concurrent exposure on the bone marrow in
these individuals is unknown. Freund et. al. investigated the combined toxicity of ZDV
and SMX-TMP in normal mice (1). Exposure to ZDV plus SMX-TMP via oral gavage
caused severe pancytopenia, a significant decrease in splenic cellularity, a significant
decrease in splenic macrophage number, and a trend toward a decrease in splenic B
lymphocytes (1). Since these differences were found in the combination treatment
group, yet the single drug groups receiving either SMX-TMP or ZDV did not differ from
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control, it was concluded that this drug combination causes a synergistic toxicity to
cellular immunity, and could be contributory to the immunosuppressive state of AIDS
patients. Additionally, combination treatment did not affect T lymphocyte populations in
the spleen (1). This could be because they mature in the thymus instead of the bone
marrow, or because in mature animals, T cell development in the thymus decreases,
and the T cell repertoire is maintained mainly by dividing T cells in secondary lymphoid
sites (177).
Because the cell types that are affected originate in the bone marrow, and because
of the known adverse affects of SMX and ZDV, we hypothesized that this is the location
of the toxicity. In this work we have extended these studies to investigate whether
SMX-TMP in combination with ZDV significantly interferes with development of cells in
the bone marrow of mice, while focusing our efforts on those of the B lymphocyte
lineage. We speculate that this drug-drug interaction could contribute to the impaired B
cell function commonly seen in HIV patients (44, 45).

D. B CELL DEVELOPMENT
Mouse bone marrow contains B lineage cells in all stages of development, as they
mature from stem cells, to common lymphoid progenitors, to early immature B cells, to
mature B lymphocytes. These cells can be characterized and phenotypically delineated
by examination of cell surface markers found on each cell type (178). Development of
B cells progresses through a series of checkpoints in which the cells display a certain
combination of these surface proteins, each with a particular function.
Cells undergo positive and negative selection processes in order to develop a B
lymphocyte population that can respond to environmental pathogens effectively, without
reacting with self antigens, thereby preventing autoimmunity. This diverse B cell
repertoire is developed by genetic recombination, and kept in check by negative
selection, which makes cells that are autoreactive undergo programmed cell death.
This is of particular interest to us, because as will be demonstrated in this work, Blineage cells undergo an increased rate of apoptosis as a result of exposure to ZDV
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plus SMX-TMP. Apoptosis occurs as a normal part of homeostasis when cells are in
the presence of a death signal or in the absence of a survival signal. We have
investigated the mechanism by which ZDV plus SMX-TMP causes apoptosis in Blineage cells.

Development mechanisms
Immature B cell subsets are defined by the assembly and expression of antigen
receptor genes and other surface proteins that distinguish the different functional stages
of development (179). Antigen specificity of each cell is determined through the
complex genetic rearrangement and recombination of genes in the variable regions of
both the heavy and light chains of the B cell receptor (BCR) (180, 181). Antibody
diversity is forged here via recombination of different gene segments, and through the
addition and subtraction of nucleotides that occurs at the joints of these genes during
this process (180).
Genetic recombination begins with the genes at the heavy chain locus under the
governance of the proteins RAG-1 and RAG-2, products of the recombination-activation
genes (182, 183). This causes the cell to express a heavy chain along with a
“surrogate” light chain that makes up the pre-BCR (184, 185). Expression of this
receptor constitutes a productive genetic rearrangement at the heavy chain locus, which
signals the cell to stop genetic rearrangement and to start dividing, thus allowing the cell
to progress to the next stages of development. This signal to stop is manifested by
degradation of RAG-2, and by suppression of mRNA synthesis for both RAG-1 and
RAG-2 (186). Cells that do not express the pre-BCR will die via apoptosis.
Cells then undergo a burst of proliferation, increasing the number of cells that
possess successfully rearranged heavy chains by 30- to 60-fold (178, 187). Cells then
upregulate RAG-1 and RAG-2 once again to rearrange the genes at the light chain loci.
Rearrangement of genes that make up the light chain will then produce the protein that
joins with the heavy chain that leads to surface expression of the BCR (IgM). If the
BCR encounters an antigen that it can cross-link to, the cell will either halt its
development and be deleted via apoptosis (high-affinity interaction), become anergic, or
revise its BCR to eliminate self-reactivity (low-affinity interaction) (188-190). This
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process of negative selection will protect the host from the development of self-reactive
lymphocytes and therefore prevent autoimmunity. In the absence of BCR binding,
genetic rearrangement ceases at this stage, and the immature B cell can be released
into the periphery.
The bone marrow contains specialized stromal cells to interact with developing B
cells in order to provide signals for growth by binding directly to the B cells, and by
secreting growth factors into the bone marrow milieu (191). B cells in their early stages
of development rely on stem-cell factor (SCF), which interacts with c-kit, a tyrosine
kinase receptor on the surface of the B cell precursor. Another molecule on the surface
of stromal cells, VCAM-1, serves as an adhesion molecule that binds to VLA-4 on the
surface of early B lineage cells in order to promote the binding of c-kit to SCF (192). B
cells in later stages of development require IL-7, a cytokine that is produced by stromal
cells to govern the proliferative burst seen in the early pre-B cell stage, discussed below
(193).

B lineage classification
Classification of B-lineage cells has been made on the basis of cell-surface proteins,
including immunoglobulin heavy and light chains, and other molecules that delineate
these cell types. Common lymphoid progenitors, derived from pluripotent stem cells
that have not yet differentiated into B-lineage cells, already express the IL-7 receptor α
chain and c-kit (194). The earliest B-lineage cells are known as pre-pro B cells and are
defined by the appearance of the B220 isoform of CD45 (195). These cells can be
identified by the lack of CD19 expression, which characterizes all later B-lineage stages
(195). Rearrangement of the immunoglobulin heavy chain locus begins during this prepro-B cell stage. B220, a tyrosine phosphatase that is involved in BCR signaling, is
expressed until B cells terminally differentiate into plasma cells (178). Initial CD19
expression marks transition to the pro-B cell stage (178). The heavy chain is also being
formed here, with RAG-1 and RAG-2 expression remaining high.
Productive intact heavy chain expression marks the transition to the pre-B cells
stages. The pre-BCR is expressed (albeit mostly intracellularly) in the early pre-B cell
stage, which halts heavy chain gene rearrangement. RAG-1 and RAG-2 down-regulate

19

here, and the cells then divide several times in a proliferative burst under the influence
of IL-7, becoming late pre-B cells. The loss of CD43 expression, the adhesion molecule
that has been present since the progenitor stages, marks the transition into this next
stage (178). The light chain genes then begin to rearrange in late pre-B cells (with the
reemergence of RAG-1 and RAG-2). Once the light chain is fully assembled and the
complete IgM molecule is expressed on the cell surface, the cell is termed an immature
B cell (178).
Other cell-surface molecules on pre-B cells include BP-1, an aminopeptidase, and
heat stable antigen (HSA). The function BP-1 in the context of B cell maturation is
unknown, but its presence allows researchers to identify and isolate the different Blineage subsets. HSA has been demonstrated to aid in cell to cell adhesion (196). BP1- and HSA-deficient mice phenotypically display no B cell abnormalities, including
number or immunologic functions (197, 198). The surface expression of these markers,
along with developmental processes occurring at each B-lineage stage is summarized
in Figure 1.1. Immature B cells will then undergo negative selection for self-tolerance,
and will leave the bone marrow, and further their development into mature B cells in
secondary lymphoid tissues. They are considered naïve until they encounter foreign
antigen and become activated.
ZDV and SMX-TMP exposure alters the progression of B-lineage cells through these
stages. We will demonstrate that specific points in development are targeted for
apoptosis as a result. This targeting of cells in sequential stages of development
ultimately becomes one hypothesis for apoptotic synergy.

E. PROJECT OVERVIEW
The immune response to HIV is complex, and many factors contribute to the success
in controlling not only HIV, but OI that afflict this patient population. Adaptive immunity
carries a large burden in protecting hosts exposed to opportunistic and other pathogens.
Assault on the bone marrow in these patients is multifactorial. While drug therapy has
been extremely effective in allowing patients infected with HIV to live longer and
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Figure 1.1 Stages of B-lineage development. The cell surface proteins B220, CD43,
HSA, and BP-1 can be used to phenotype B-lineage cells via flow cytometry. RAG-1
and RAG-2 expression are up-regulated for heavy- and light-chain gene rearrangement,
and down-regulated for the proliferative burst in the early pre-B cell stage. The BCR is
then expressed on the cell surface (IgM) in immature B cells. CLP, common lymphoid
progenitor. Adapted from Hardy et. al., 1990 (199).

healthier lives, clinicians and researchers must consider that these drugs also alter the
number and function of immune cell populations, and can have a negative impact on the
treatment of this complex disease state. Patients should be treated cautiously with
many of these drug combinations, and any hematological abnormalities identified
should be investigated as potential iatrogenic reactions to agents being used.
To this end, we investigated this drug-drug interaction concerning concurrent
exposure of ZDV and SMX-TMP. We first began in a mouse dosing model to verify the
findings of others concerning peripheral immune cell effects, and then we focused on
the bone marrow as a target of this toxicity. This investigation led us to a study of the
mechanisms at work in the bone marrow, focusing on B-lineage cell subtypes. Because
these drugs in combination were rendering cells in the bone marrow apoptotic, we then
investigated the mechanism of apoptosis induction in a series of in vitro experiments.
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Next we determined that this toxicity has an adverse affect on host defense by
examining the immune response in mice challenged with a pulmonary infection
with Pneumocystis murina after being dosed with ZDV plus SMX-TMP. Because the
responses in the mice treated with the drug combination were altered, we conducted a
human trial to determine the clinical significance of combining ZDV with SMX-TMP
treatment in patients infected with HIV. The humoral response to the yearly influenza
vaccine was measured in patients receiving ZDV, SMX-TMP, the combination of both,
or neither drug. Data presented suggests a clinically-significant impact on host
response due to exposure to ZDV plus SMX-TMP.

Copyright © David James Feola 2005
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CHAPTER 2: Combination exposure to ZDV and SMX-TMP in normal mice

A. OVERVIEW
Our investigation of the toxic effects of combination exposure to ZDV and SMX-TMP
in mice began with a characterization of cellular toxicity in the spleen, peripheral blood,
and pulmonary tissues to confirm the results of others, and with an in-depth
investigation of the effects on bone marrow cell populations in these animals (1).
Phenotypic analyses of cell types including neutrophils, monocytes, and T and B
lymphocytes in peripheral lymphoid tissues formed the basis of further study directed
toward the bone marrow. Because cell types that mature in the bone marrow were
most affected, we sought to characterize bone marrow cell population dynamics, as well
as to elicit the mechanism of the toxicity, focusing on B lymphocytes.
We hypothesized in Chapter 1 that the site of immunotoxicity in mice as a result of
ZDV plus SMX-TMP exposure is the bone marrow. We sought to demonstrate that the
mode of cell death (apoptotic versus necrotic) as a result of exposure to ZDV plus SMXTMP. We then characterized the kinetics of this toxicity in B lineage cell populations as
they evolve through the different checkpoints on the way to becoming mature B cells.
To explain the mechanism of cell death, we then demonstrated that the effect is cellcycle specific, primarily affecting early pre-B cells as they undergo the proliferative burst
into the late pre-B cell phenotype.

B. MATERIALS AND METHODS

Materials
ZDV (3’-azido-3-deoxythymidine), trimethoprim (2,4-diamino-5-[3,4,5-trimethoxybenzyl]pyrimidine), SMX (4-amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide),
methylcellulose, sodium azide, DMSO, PBS, ammonium chloride, potassium
bicarbonate, EDTA, collagenase A, DNase, caffeine, acetonitrile, acetic acid,
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triethylamine, and RNase A were obtained from Sigma-Aldrich (St. Louis, MO).
Monoclonal Abs, including FITC-conjugated GR-1, IgD, and BP-1, PE-conjugated CD19
and CD43, APC-conjugated CD11b, B220, and CD8, PE-cyanine-conjugated CD4, and
biotinylated CD43 and heat stable antigen (HSA), were obtained from BD Pharmingen
(San Diego, CA). Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (BD
Pharmingen) was utilized for identifying cells undergoing early stages of apoptosis.
RPMI Medium 1640, HBSS, and FCS were purchased from Gibco Invitrogen
Corporation, Grand Island, NY.

Animals
Four- to six-week old normal BALB/c mice were obtained from the National Cancer
Institute (Raleigh, NC) and isolated for at least 7 days before manipulation. Mice were
housed in the Veterans Administration Veterinary Medical Unit under pathogen free
conditions with a 12 hour light/dark photocycle and food and water both freely available.
This study and all of its procedures were approved by the Veterans Administration
Institutional Animal Care and Use Committee.

Drug preparation and dosing design
Drug doses were prepared daily by weighing each powder into polypropylene tubes,
SMX and TMP together, and ZDV separately, and suspending each in its appropriate
vehicle: ZDV dissolved into sterile-filtered deionized H20 to a concentration of 50mg/ml,
SMX and ZDV suspended in 0.5% methylcellulose in H20 at concentrations of 106mg/ml
and 8mg/ml, respectively. Mice were randomized into four treatment groups, either
receiving ZDV or SMX-TMP alone, in combination, or vehicle only (control), at the
following doses based on an approximate mean mouse weight of 20 grams: ZDV
240mg/kg (5mg per mouse in 100µl), SMX 840mg/kg (16mg per mouse in 150µl), and
TMP 160mg/kg (1.2mg per mouse). Doses were given via oral gavage with an 18gauge blunt-tipped dosing needle, and mice received each drug or its corresponding
vehicle daily.
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Tissue processing
Spleens were collected in RPMI-1640 supplemented with 5% FCS, weighed, and
pushed through mesh screens to obtain single cell suspensions. Lungs were minced
and digested by incubation with 50 U/ml DNase and 1mg/ml collagenase A and pushed
through mesh to form single cell suspensions. Peripheral blood specimens were
collected from the abdominal aorta and placed in heparinized tubes to prevent clotting.
Blood was also collected separately in dry tubes, allowed to clot, and serum was
separated by centrifugation and frozen at -800C until time of SMX concentration
analysis. Bone marrow was flushed from femurs and tibias into RPMI-1640 plus 5%
FCS, and single cell suspensions were obtained via passage through a 25-gauge
needle. Red cells in all samples were lysed with hypotonic buffer consisting of 0.15M
ammonium chloride, 10mM potassium bicarbonate, and 0.1mM EDTA. Cells were then
washed, enumerated, and transferred into 5ml round-bottom polystyrene tubes for
phenotyping via flow cytometry.

Cell phenotyping
Splenocytes and lung digest cells were incubated with fluorescently-labeled mAb
specific for murine cell surface markers, including major histocompatibility complex II
(MHC II), CD19, CD4, and CD8. Bone marrow cells were incubated with 3 separate
panels of Abs to phenotype B lineage cell types in addition to polymorphonuclear cells
(PMN). Panel 1 consisted of CD19, granulocyte differentiation antigen (GR-1), and
CD11b (component of Mac-1); panel 2 of B220, CD43, BP-1, and HSA; panel 3 of
B220, CD43, and IgM. B lineage cells were classified according to nomenclature
developed by Hardy et al (178). Cells were washed before and after staining with PBS
containing 0.1% BSA and 0.02% sodium azide. All cells were analyzed for phenotype
by flow cytometric multiparameter analysis using a FACSCaliber Flow Cytometer (BD
Biosciences, Mountain View, CA). Greater than 50 thousand events per sample were
routinely examined.
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Apoptosis analysis
The proportion of apoptotic cells was quantified using the annexin-V binding protocol
with PI exclusion. Annexin binds to phosphatidylserine groups that are externalized on
the cell membrane in early stages of apoptosis (59). Samples were analyzed by flow
cytometry as above, and cells that fluoresced annexin-V positive/PI negative were
considered apoptotic.

Cell cycle analysis
Individual B cell subpopulations were fluorescently labeled as above and sorted
using fluorescence-activated cell sorting (FACS) with a MoFlo high speed cell sorter
and analyzer from Cytomation (Fort Collins, CO). Subpopulations were then fixed using
95% ethanol, and stored at -200C. Cell cycle analysis was performed by labeling DNA
with PI at 50µg/ml in the presence of 50µg/ml RNase A. A FACSCaliber flow cytometer
was used to analyze cell cycle stages with doublet discrimination, using the ModFit
software package (Verity Software House, Inc, Topsham, Maine).

Statistical Analysis
Data was compared using one-way ANOVA followed by the Student-Neuman-Keul
test for ad hoc pair-wise comparisons. Each treatment group was compared to its
corresponding control using commercially available software (Sigmastat, SPSS,
Chicago, IL). Data that failed normality testing was compared using the Kruskal-Wallis
One Way Analysis of Variance on Ranks method. Results were determined to be
statistically significant when a p-value < 0.05 was obtained. Data are expressed as the
mean ± standard deviation.

C. RESULTS

Combination dosing has an overall clinical effect on mice
Mice were dosed with ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only for a
period of 28 days. Doses were chosen based on previous studies that produced
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significant levels of toxicity. Daily oral gavage of ZDV plus SMX-TMP led to an increase
in lethargy, failure to groom, and a hunched appearance by day 28, though no mortality
occurred. Mice in this group displayed a decrease in body weight after 28 days of
dosing, whereas the ZDV, SMX-TMP, and control groups all gained weight (Table 2.1).
Spleen weights and spleen weight expressed as a percentage of body weight were
reduced in the combination group compared to the control group, with each single-drug
treatment cohort again displaying no difference (Table 2.1). Other organs in the
peritoneum did not display any gross changes upon examination.
Table 2.1 Body and spleen weights.
Mouse weight (grams)
Day 0A

Day 28

Change

Grams

Percent
body weight

ZDV

18.73 ± 1.50

19.42 ± 1.41

0.68 ± 0.77

0.078 ± 0.027

0.40 ± 0.14

SMX-TMP

18.43 ± 0.70

20.64 ± 1.06

0.086 ± 0.009

0.42 ± 0.03

Mouse Group

A
B

Spleen weight (Day 28)

2.12 ± 0.37
B

B

B

ZDV + SMX-TMP

17.99 ± 0.49

17.16 ± 1.26

-0.83 ± 1.28

0.040 ± 0.008

0.23 ± 0.04B

Control

18.39 ± 1.42

20.28 ± 1.37

1.89 ± 0.73

0.090 ± 0.012

0.44 ± 0.06

p-value

0.816

0.005

0.001

0.002

0.016

Data expressed as mean ± SD of 5 mice per group.
p < 0.05 compared to control group.

B lymphocyte and granulocyte populations are decreased by ZDV plus SMX-TMP
treatment, primarily in the bone marrow and spleen
We conducted a phenotypic analysis of immune cell populations in the spleen, lungs,
and bone marrow of mice treated with the drug combination. Splenic cellularity
decreased 49% in the ZDV plus SMX-TMP group after 28 days of therapy as compared
to control, whereas the ZDV and SMX-TMP groups were not significantly affected
(Figure 2.1A). The cell types that accounted for this decrease were the splenic
monocytes and B lymphocytes in the ZDV plus SMX-TMP group, as shown in Figure
2.1B. No differences were observed in splenic CD4+ and CD8+ T cell numbers.
Peripheral blood lymphocyte percentages were not significantly affected at any
timepoint examined, with data shown for mice after10 days of drug exposure
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Figure 2.1 Effects of drug dosing on immune cell populations. Mice were treated with
either ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only control. Spleen, peripheral
blood, and lung digests were processed into single-cell suspensions and phenotyped by
flow cytometry. Panels consist of: (A) total splenocytes isolated from mice in each
group after 28 days dosing; (B) CD4+ and CD8+ T cells, monocytes (MHC II+ on nonlymphocyte gate) and CD19+ B cells in spleens; (C) percentages of CD4+, CD8+, and
CD19+ cells in peripheral blood after 10 days of dosing; and (D) CD4+ and CD8+ T cells,
macrophages (MHC II+ on non-lymphocyte gate) and CD19+ B cells in lung digests after
28 days drug exposure. Data represent the mean ± SD of 4 mice per group and are
representative of 3 separate experiments. Significant differences from control group (*)
were defined at an alpha level of < 0.05.

(Figure 2.1C). Lung digest cell populations (Figure 2.1D) displayed no differences in
total cell number or in any subpopulation of cells quantified.
There were significant decreases in all cell lineages examined in the bone marrow in
mice receiving combination exposure, including total cells, B lymphocytes, and PMN
(Figure 2.2A). There was a dramatic decrease in bone marrow cellularity at all
timepoints in the ZDV plus SMX-TMP group as compared to the control group (Figure
2.2B). Bone marrow B cells (B220+) are depicted in Figure 2.2C, demonstrating that
they follow the same pattern of depletion over time as the total bone marrow cell
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Figure 2.2 Effects of drug dosing on bone marrow B cell populations. Mice were
treated with either ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only control. Bone
marrow cells were isolated from femurs and tibias of mice and processed into single cell
suspensions after RBC lysis. Panel A depicts total cell, PMN (GR-1+/CD11b+), and B
cell (B220+) populations in the bone marrow after 28 days of dosing. The next panels
show the kinetics of the depletion of total cells (B) and B220+ B cells (C) over time up to
day 28 of drug exposure. Data represent the mean ± SD of 4 mice per group and are
representative of 3 separate experiments. Significant differences from control group (*)
were defined at an alpha level of < 0.05.

populations. Notably, treatment with either drug alone had no statistically significant
effect on any cell populations in the bone marrow, spleen, or lung digest at any
timepoints examined (Figures 2.1 and 2.2).

B lineage subtypes in the bone marrow are affected primarily at the late pre-B cell
stage
B cell development proceeds through discreet stages, allowing us to determine in
vivo toxic effects of ZDV plus SMX-TMP on B cell maturation. Phenotypic analysis via
flow cytometry according to the scheme developed by Hardy et al, 1991 is depicted in
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Figure 2.3 (178). When expressed as percentages, large deviations in B lineage cells
were not observed, with the exception of late pre-B cells (Figure 2.3B). Representative
histograms from flow cytometry analysis show the absence of late pre-B cells in a
mouse dosed with ZDV plus SMX-TMP (Panel A, region c, 0.6% of the total bone
marrow) compared to a control mouse (Panel B, 6.6% of the total bone marrow).

A
a

0.6%

0.12%

b

4.2%
14.2%

f

e

BP-1

B220

c

1.6%
d

2.3%

B

18.0%

6.6%

BP-1

B220

0.09%
3.6%

2.0%

1.2%
IgM

CD43

HSA

Figure 2.3 Phenotypic staining of B cell precursors by flow cytometry. Bone marrow
from mice treated with ZDV plus SMX-TMP for 9 days (A) are compared to bone
marrow from control mice (B). Cells were gated on lymphocyte populations and stained
for B220 and CD43 (middle panels). Lymphocytes in gate a (B220+/CD43-) in the
middle panels were stained for IgM (left panels) to determine late pre-B cell percentage
shown in box c (B220+/CD43-/IgM-). B220+/CD43+ cells (gate b) were then analyzed for
HSA vs. BP-1 (right panels). Pre-pro-B cells are shown in box d (B220+/CD43+/HSA/BP-1-), pro-B cells in box e (B220+/CD43+/HSAlow), and early pre-B cells in box f
(B220+/CD43+/ HSAhigh/BP-1+).

Absolute cell numbers of B-lineage subtypes are shown in Figure 2.4. Differences
observed were in large part due to differences in overall bone marrow cell counts, and
not alterations in percentages of each cell type (as described above). There was a
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significant decrease in pre-pro-B cells (B220+/CD43+/BP-1-/HSA-) compared to the
control group after 21 days of combination dosing (Figure 2.4A). In the single drug
treatment groups, decreases in number of pre-pro-B cells were seen at day 28, similar
to those seen in the combination treatment mice (Figure 2.4A). The pro-B cell fraction
(B220+/CD43+/HSAlow) displayed similar kinetics, with a significant decrease in cell
number in the combination group occurring at the 21- and 28-day timepoints (Figure
2.4B). Pro-B cell numbers were also significantly decreased in the ZDV group at day 21
and the SMX-TMP group at day 28.
The early pre-B cell population (B220+/CD43+/BP-1+/HSA+) was approximately three
times greater in number at day 7 in the ZDV plus SMX-TMP treated mice compared to
the control animals (Figure 2.4C). By day 28, however, this population fell
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Figure 2.4 Kinetics of B lineage subsets at weekly timepoints. Mice were treated with
either ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only control, and sacrificed at
weekly time intervals. B220+ B cells were phenotyped for surface marker profiles using
flow cytometry as shown in Figure 3. Cell fractions were enumerated in developmental
sequence, including pre-pro-B (A), pro-B (B), early pre-B (C), and late pre-B cells (D).
Bars represent the mean ± SD of 4 mice per group per timepoint. Significant difference
to control group (*) was defined at an alpha level of < 0.05.
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significantly as compared to the control group. Interestingly, the rise in early pre-B cells
corresponded to a decrease in the late pre-B cell (B220+/CD43-/IgM-) fraction on day 7.
Late pre-B cell numbers were dramatically lower on the later 3 timepoints in the
combination treatment group (Figure 2.4D). The increase in cell numbers among the
late pre-B cell fraction in comparison to the other B cell subtypes corresponds to the
proliferative burst seen as they mature from the early pre-B cell stage to the late pre-B
cell stage of development under the influence of IL-7. This proliferative burst was
absent in the ZDV plus SMX-TMP group at days 15, 21, and 28 of therapy (Figure 2.4C
and 2.4D).

The mode of cell death is apoptosis
To gain insight into the mechanism of bone marrow cell depletion, the percentage of
cells undergoing apoptosis was determined by identifying cells that were bound to
annexin V but stained negative for PI. There was a significant increase in percentage of
total cells that stained annexin +/PI- in the ZDV plus SMX-TMP group at each timepoint
examined (Figure 2.5A). The combination of drugs caused a significant increase in
apoptotic cells in both the non-lymphocyte and B lineage populations. Statistically
significant increases were observed at each timepoint for percentages of nonlymphocytes (identified via a non-lymphocyte gate) undergoing apoptosis in the
combination treatment group (Figure 2.5B). Percentages of total B cells (B220+)
undergoing apoptosis were significantly increased at the 7-, 15-, and 28-day timepoints
in the ZDV plus SMX-TMP group, with a trend toward significance at day 21 (p=0.07) as
shown in Figure 2.5C.
Pro-B (B220+/CD43+) and pre-B (B220+/CD43-) cell subpopulations were examined
for induction of apoptosis. Percentages of apoptotic pro-B cells were increased at the
15-, 21-, and 28-day timepoints, more than doubling in each instance in the ZDV plus
SMX-TMP group as compared to the group receiving vehicle (Figure 2.5D). The
percentage of pre-B cells undergoing apoptosis was significantly increased at days 7,
15, and 28 in the combination treatment group, again at more than twice the apoptosis
rate as the control group (Figure 2.5E). There were no differences in percentage of B-
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lineage cells undergoing apoptosis in either of the single drug treatment groups as
compared to the control group (Figure 2.5). Additionally, we have also demonstrated
this effect from the drug combination in FVB/N mice, to confirm that the toxicity is not
strain-specific to BALB/c mice. This data is shown in Chapter 3 (Figure 3.8).
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Figure 2.5 Percentages of apoptotic cells at weekly timepoints of drug dosing. Mice
dosed with ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only control were sacrificed
at weekly timepoints and the bone marrow aspirates were assayed for cells undergoing
apoptosis. Cells that labeled annexin-V positive, PI negative were deemed apoptotic.
Percentages of total cells (A), non-lymphocytes (B), B lymphocytes (C), pro-B cells (D),
and pre-B cells (E) are shown. Data represents the mean ± SD and are representative
of 3 separate experiments. Significant differences (*) from control group were
determined at an alpha level of <0.05.
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Long-term, low-dose exposure did not affect the bone marrow
To determine the long-term affect of ZDV plus SMX-TMP on the bone marrow, mice
were dosed with ZDV, SMX-TMP, the combination of both, or vehicle only control as
described previously. Dosing was altered for this experiment however, in that the doses
were reduced 8-fold, to ZDV 30mg/kg, SMX 105mg/kg, and TMP 20mg/kg, and the
dosing duration was extended to 55 days. These doses were chosen because of
preliminary data that demonstrated a low level of bone marrow toxicity at these
quantities over a dosing period of 14 days. Figures 2.6A and 2.6B show that total cells
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Figure 2.6 Long-term dosing effect on bone marrow total and B cells. Mice were
dosed with ZDV, SMX-TMP, the combination of both, or vehicle only control as
described in Materials and Methods. Dose was reduced however to ZDV 30mg/kg,
SMX 105mg/kg, and TMP 20mg/kg, and the dosing duration was extended to 55 days.
Panels A and B depict percentages of total cells (A) and B220+ B cells (B) harvested
that were dead (annexin-V positive, PI positive) or apoptotic (annexin-V positive, PI
negative). Panel C represents mean final mouse weights on day 55 of dosing. Panel D
shows the total cell counts in the bone marrow at the time of harvest. Data represents
the mean ± SD and are representative of 1 experiment only. Significant differences (*)
from control group were determined at an alpha level of <0.05.
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(A) and B220+ B cells (B) were not affected after exposing the mice to low levels of drug
for 55 days. Dead (annexin-V positive, PI positive) and apoptotic (annexin-V positive,
PI negative) cell percentages were unaffected in the combination dosing group
compared to the control group. Interestingly, dead and apoptotic B cell percentages in
the SMX-TMP group were significantly reduced. Panel C represents the mean final
mouse weights on day 55 of dosing, which were not affected by SMX-TMP or ZDV.
Panel D shows the total cell counts in the bone marrow at the time of harvest, which
also displayed no statistically-significant differences in the treatment groups compared
to control.

The toxicity to B lineage subpopulations is cell-cycle specific
We have demonstrated that the transition from the early pre-B to the late pre-B cell
stage appears to be affected by the drug combination, as evidenced by an accumulation
of early pre-B cells followed by depletion of late pre-B cells at day 7 of drug exposure.
To determine whether this was due to cell cycle arrest, mice from the four treatment
groups were sacrificed after 6 and 9 days of dosing for bone marrow harvest and cell
cycle analysis. Bone marrow was pooled from each group, and sorted by flow
cytometry into pre-pro-B, pro-B, early pre-B, and late pre-B cell subsets. Cells were
fixed and stained with PI for cell cycle analysis on the sorted samples. Samples were
pooled to acquire enough events for analysis after sorting because some subtypes exist
at very small percentages of the total bone marrow.
Representative cell cycle histograms are shown in Figure 2.7 to illustrate the marked
accumulation of cells in the S and G2/M phases of the cell cycle as a result of dual drug
treatment. Mice treated with ZDV plus SMX-TMP displayed an increased proportion of
early pre-B cells in S phase and G2/M phases compared to the control mice after 6 and
9 days of treatment (Fig 2.7A-C). Panels D through F show late pre-B cells, which had
an overall proliferation rate that is lower than that of early pre-B cells. Combination drug
dosing did not alter the proportion of S phase late pre-B cells to a large degree,
however there was an upward trend compared to the control group (Figure 2.7D-F).
The fraction of cells in S phase and G2/M phases for all groups are shown in Figure
2.8. After 6 days of dosing, the proportion of pre-pro-B, pro-B, and early pre-B cells in

35

Late Pre-B Cells

600

D

A
Number

400
300

G0/G1 = 68.87
S = 23.05
G2/M = 3.14

G0/G1 = 88.50
S = 8.26
G2/M = 1.52

100

B

600

150

200

250

FL2-H

Number

400

500

Day 6, ZDV + SMX-TMP

300

G0/G1 = 49.10
S = 39.68
G2/M = 10.50

50

100

150

200

250

FL2-H

E

Day 6, ZDV + SMX-TMP
G0/G1 = 83.46
S = 12.44
G2/M = 1.36

0

0

100

0

200 400 600 800 1000 1200 1400

50

200
600

0

50

100

150

200

C

300
200

50

100

150

200

250

FL2-H

F

Day 9, ZDV + SMX-TMP
G0/G1 = 82.56
S = 14.58
G2/M = 1.86

0

0

100

Number

400

500

Day 9, ZDV + SMX-TMP
G0/G1 = 54.24
S = 36.32
G2/M = 8.06

0

250

FL2-H

200 400 600 800 1000 1200 1400

Number

Control

0

0

100

200

Number

500

Control

0

Number

200 400 600 800 1000 1200 1400

Early Pre-B Cells

0

50

100

150

200

250

FL2-H

0

50

100

150

200

250

FL2-H

Figure 2.7 Bone marrow B lymphocyte cell cycle histograms. Bone marrow samples
were analyzed for cell cycle profile by measuring PI intercalation into DNA (expressed
as fluorescence intensity) on day 6 and day 9 of dosing with ZDV, SMX-TMP, ZDV plus
SMX-TMP, or vehicle only. B220+ cells from bone marrow were phenotyped by surface
markers and sorted via flow cytometry prior to cell cycle analysis. The panels on the left
depict the cell cycle profiles in the early pre-B cell populations from mice treated with
the combination of ZDV and SMX-TMP on day 6 (B), and day 9 (C), as compared to
control mice (A). The panels on the right depict late pre-B cells in the control group (D)
and the ZDV plus SMX-TMP group at day 6 (E) and day 9 (F) of dosing. The
proportions of cells in the different phases of the cell cycle are shown on each panel.
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the S and G2/M phases were higher in the combination drug treatment group than in the
other groups (panels A and B). This proliferative burst is exaggerated on day 6 of
dosing in the combination group. However, by day 9, the percentage of cells in S phase
and G2/M phases show no obvious differences in any of the B lineage subsets (panels
C and D).
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Figure 2.8 Cell cycle analysis. Cell cycle analysis experiments were performed by
sorting B lineage subpopulations into pre-pro-B, pro-B, early pre-B, and late pre-B cell
fractions by FACS as per Figure 5. Bone marrow from mice treated with ZDV, SMXTMP, ZDV plus SMX-TMP, or vehicle was pooled together (3 mice per group) and
sorted after 6 and 9 days of dosing. Cell cycle analysis was performed using PI
intercalation and FACS. The percentage of each subpopulation in each stage of the cell
cycle is reported. Panels A and B depict percentages of B lineage cells from mice
treated for 6 days that are in S phase and G2/M phases, respectively. Panels C and D
show the percentage of cells in S phase and G2/M phases from mice treated with the
drugs for 9 days. Data are representative of 2 separate experiments.
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D. CONCLUSIONS
We have demonstrated the toxic effects of the combination of ZDV and SMX-TMP
on B cell development in a mouse model. Bone marrow cells in mice treated with the
drug combination had a significantly higher incidence of apoptosis and the combination
of drugs appears to affect the proliferative burst as B lineage cells multiply in the pre-B
cell stage of development. Interestingly, we consistently found a temporal relationship
between drug administration and stage of which B cell development was compromised.
We observed a significant increase in early pre-B cells at the IL-7-dependent
proliferative burst at day 7 of drug treatment. However, there was a marked decrease in
the numbers of cells in the late pre-B cell fraction, suggesting that ZDV plus SMX-TMP
treatment blocked transition into this stage. The cell cycle data presented in Figure 2.7
shows an increased percentage of cells in the S and G2/M phases in the combination
group, which could be indicative of either cell cycle arrest or increased proliferation.
Taken together with the data demonstrating cellular depletion and apoptosis, we
conclude that it is indicative of arrest.
In subsequent timepoints, this increased pre-B cell population is abolished, and cells
in the earlier stages of development (pro-B) are decreased. It appears that over time,
the toxicity of ZDV plus SMX-TMP causes fewer cells to reach the pre-B cell stage
resulting in a depletion at this stage. Of note, after dosing for 28 days, proportions of
pre-pro-B and pro-B cells were significantly reduced in each single drug treatment
group; however, the total bone marrow B lymphocyte population in these mice was not
significantly affected suggesting that the presence of the drugs in combination is
required to block the IL-7 dependent pre-B cell expansion. Our data demonstrate that
the cell type most affected is that which is undergoing the most cell division; this is
consistent with the known propensity of ZDV and SMX-TMP to affect DNA replication
during the S phase.
To further these investigations, we have expanded these studies in two ways. First,
we describe the characteristics of this toxic effect in a series of in vitro experiments, as
we analyze the apoptotic mechanism in these cells that are affected by the drugs.
Secondly, we investigate in mice the affect of this drug-drug interaction on the host’s
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ability to respond to an infectious agent. These studies will ultimately lead to the human
trial that exposes the clinical significance of this toxicity, which will be presented in
Chapter 5.

Copyright © David James Feola 2005
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CHAPTER 3: Mechanistic investigation of toxicity to B lymphocytes due to ZDV
plus SMX-TMP exposure

A. OVERVIEW
In the previous chapter, we have characterized the effects of combination exposure
to ZDV and SMX-TMP in mice. Because this toxicity affects cells that originate and
mature in the bone marrow, we have focused our studies to this tissue to demonstrate
that cells are being induced to undergo a higher rate of apoptosis when exposed to both
drugs. B-lineage cells are primarily affected at the proliferative burst when transitioning
from the early pre-B cell stage to the late pre-B cell phenotype; however, in addition,
fewer progenitors are reaching this stage of development. In this chapter we now report
a series of in vitro experiments designed to further characterize the toxicity of ZDV plus
SMX-TMP exposure, along with additional in vivo assessments to investigate the
mechanism of enhanced apoptosis in B lymphocytes.
While there is little in the literature addressing the toxicity of these agents in
combination, the cytotoxic effects of both SMX-TMP and ZDV individually have been
extensively studied. Several groups have shown that ZDV affects lymphocytes in their
early stages of development in the bone marrow (107-109). The monophosphorylated
form is responsible for its toxicity by inhibiting thymidylate kinase and lowering
intracellular thymidine pools, as discussed in Chapter 1 (107). This toxicity is
associated with an inhibition of hematopoietic progenitors in murine and human bone
marrow (108, 109). ZDV induces apoptosis in immune cell populations by this inhibition
of DNA synthesis, having the greatest impact on cell types that are actively cycling (111,
112). ZDV monophosphate also induces mitochondrial dysfunction in hematological
cells due to inhibition of mitochondrial DNA polymerase gamma (113-116). This
mechanism of toxicity also plays a role in apoptosis induction, as it is thought that ZDV
makes cells more susceptible to apoptosis by inducing mitochondrial membrane
hyperpolarization (112, 117).
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Effects of SMX-TMP on bone marrow cell populations have been well studied. The
toxicity has been attributed to the oxidative metabolites of SMX, sulfamethoxazolehydroxylamine (SMX-HA) and nitroso-sulfamethoxazole (SMX-NO), based on in vitro
data (152). Incubation of neutrophils and lymphocytes with the parent compound SMX
caused little or no toxicity, while cytotoxic effects were demonstrated with SMX-NO and
SMX-HA exposure, including cellular haptenation, direct cellular cytotoxicity, and, of
importance to this dissertation, apoptosis induction (152). The cellular haptenation of
SMX-HA has been shown to induce a population of SMX-HA-specific T cell clones that
are implicated in SMX hypersensitivity (200). Anti-SMX antibodies have also been
found in the serum of HIV-infected patients being treated with the drug (201). These
data are indicative of an immune pathogenesis for the toxicity associated with the drug,
along with direct cytotoxic effects observed with the metabolites.
A higher than normal incidence of adverse reactions is associated with the use of
SMX-TMP in patients with AIDS (149-151). Virus-induced GSH depletion has become
the leading hypothesis for the mechanism of this phenomenon. Patients with HIV
infection have depleted intracellular GSH concentrations, a molecule responsible for the
conversion of SMX-HA and SMX-NO back to the parent compound , which is then
metabolized to non-toxic species and eliminated (153, 154, Cribb #89, 156).
Investigators have linked this depletion of GSH by the virus to SMX-TMP intolerance in
HIV-infected patients (153, 154). Naisbitt et. al. confirmed this hypothesis by
demonstrating in vitro that the addition of GSH to cultured lymphocytes decreases SMXHA- and SMX-NO-induced cellular toxicity (202).
Additionally, in vitro studies have shown that GSH inhibits SMX-NO haptenation to
lymphocytes and neutrophils, and the CD4+ T cell response to SMX-HA haptenation in
this setting is also decreased (152, 200). Cysteine, another molecule capable of
reducing these metabolites has been demonstrated to be protective of these effects as
well (152). Although GSH depletion has not been linked to an increase in SMX
metabolite concentrations in a clinical setting, this could explain the increased rate of
toxicity seen with the use of SMX-TMP in patients with AIDS. Figure 3.1 represents the
intracellular metabolic pathways of SMX, and the roles of oxidation and reduction that
lead to its elimination. The parent is oxidized to SMX-HA by intracellular cytochrome
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P450 isoenzyme 2C9 (CYP2C9), which is further oxidized spontaneously to SMX-NO.
GSH (as well as other reducing agents) detoxify the compound back to the parent SMX,
which can be glucuronidated by the liver into hydrophilic species that are eliminated
(156, 203).
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CYP/NAPH reductase
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-GSH
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R

R

Sulphinamide

Semi-mercaptal

Figure 3.1 Intracellular metabolism of SMX. SMX is oxidized to the bioactive SMX-HA
by CYP2C9, and oxidized further spontaneously to SMX-NO. GSH, through a series of
reduction steps, converts the molecule back to the parent compound (or via CYP/NAPH
reductase) to be metabolized in the liver to glucuronidated intermediates and
eliminated. Adapted from Gill et al, 1996 (204). R=SO2-NH-C3HNO-CH3

One hypothesis we explored is that ZDV affects the disposition of SMX and its
metabolites, thereby increasing the apoptosis rate in bone marrow B cells. One
possible explanation for this alteration could lie in the interesting body of literature
describing the up-regulation of the multi-drug resistant protein 4 (Mrp4) by nucleoside
42

reverse transcriptase inhibitors (205, 206). ZDV is also a known substrate of this
transporter, and has also been recently shown to induce its up-regulation (207). Mrp4 is
known to be able to transport GSH from inside cells to the extracellular space, causing
decreases in intracellular GSH pools (208). Since GSH detoxifies SMX metabolites by
reducing them back to the parent drug, up-regulation of Mrp4 by ZDV could lead to a
buildup of toxic SMX metabolites. Alternatively, since Mrp4 also transports GSHsubstrate complexes (including GSH-SMX-HA), another potential hypothesis is that by
competitive inhibition, ZDV (also a substrate of Mrp4) decreases the amount of GSHSMX-HA complexes that are effluxed, thereby increasing intracellular concentrations of
the toxic metabolite.
Clinical investigations into the significance of this drug interaction are difficult, due to
the multiple additional factors that could be affecting immune response in HIV-infected
patients. Therefore, in addition to exploring this toxicity in an animal model, we
investigated the toxicity of this combination of compounds on mouse bone marrow in an
in vitro culture system. By doing so, many questions concerning this drug interaction
could be addressed, including dose dependency, drug disposition, and mechanism of
apoptosis induction. Our hypotheses were three-fold: first, that cytotoxicity caused by
ZDV plus SMX-TMP is concentration-dependent, synergistic, and related to oxidative
stress; second, that apoptosis induction proceeds through signaling pathway that
utilized caspases; and third, that the disposition of SMX is altered in mice as a result of
concurrent ZDV treatment.

B. MATERIALS AND METHODS

Materials
Many materials used in these experiments were obtained as indicated in previous
chapters. In addition, IL-7, dimethylsulfoxide (DMSO), 2-mercaptoethanol (2-ME),
trypan blue, etoposide, caffeine, acetonitrile, acetic acid, and triethylamine were
obtained from Sigma-Aldrich (St. Louis, MO). SMX-HA and SMX-NO were synthesized
and obtained from Dalton Chemical Laboratories (Toronto, Ontario, Canada). The pan-
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caspase inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone (Z-FAD-FMK) was purchased
from Alexis Biochemicals (Lausen, Switzerland).

BM isolation
Four- to six-week old normal BALB/c mice were obtained from NCI (Raleigh, NC)
and isolated for at least 7 days before manipulation. Mice were housed in the Veterans
Administration (VA) Veterinary Medical Unit in sterile cages with a 12 hour light/dark
photocycle and food and water both freely available. This study and all of its
procedures were approved by the VA Institutional Animal Care and Use Committee.
Mice were sacrificed using a carbon dioxide chamber, and bone marrow was promptly
isolated from femur and tibia bones under sterile conditions using 25-gauge needles
into media containing RPMI-1640, 2-ME (1x10-5 M), and 5% FCS.

Cell culture
After red cell lysis, cells were placed into 24-well culture plates at a concentration of
1x106 cells/ml per well. B lineage cell proliferation was stimulated by the addition of IL-7
at a concentration of 25 units/ml. SMX-NO, SMX-HA, and ZDV were then dissolved
using DMSO (resultant DMSO amount never exceeding 1% in any culture well) and
placed into cell culture at increasing concentrations, so that concentration-related
toxicities could be analyzed. All cultures were incubated at 370C and 5% CO2.
Variations in culture conditions, incubation times, and additives were performed in
respective experiments.

Bone marrow phenotyping
Cells were analyzed for phenotype by flow cytometry by using a FACSCaliber Flow
Cytometer (BD Biosciences, Mountain View, CA) and the WinList software package
(Verity Software House, Topsham, ME). BM cells were incubated with 3 separate
panels of fluorescently-labeled antibodies to phenotype B lineage cell types using IgM,
CD43, B220, BP-1, and HSA as described in Chapter 2. Other experiments only
required one surface marker labeling, either B220 or CD19, to classify B cells more
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generally. Cells were washed before and after staining with PBS containing 0.1% BSA
and 0.02% sodium azide.

Apoptosis assays
Bone marrow cells were analyzed via flow cytometry for apoptosis using the Annexin
V-FITC/PI assay kit, utilizing the manufacturer’s instructions (BD Pharmingen, San
Diego, CA). Briefly, cells were washed and resuspended in annexin binding buffer and
incubated in the presence of annexin-V-FITC and PI for 20 minutes at room
temperature. Cells were analyzed by flow cytometry within 1 hour.
Cells were also analyzed for apoptosis with the “Tunel” assay using the APOBRDU™ Kit (BD Pharmingen, San Diego, CA). Treated cells were fixed in 4%
paraformaldehyde for 1 hour. Terminal deoxynucleotidyltransferase (TdT) enzyme was
used to catalyze the addition of bromolated deoxyuridine triphosphate (BrdU) to the 3’hydroxyl termini of DNA for 60 minutes at 370C. Cells were washed and stained with
anti-BrdU antibody labeled with FITC, along with PI, for 30 minutes at room
temperature. Apoptosis and cell cycle were analyzed simultaneously by flow cytometry
within 3 hours.

Dose-effect analysis
To determine whether the in vitro interaction between ZDV and SMX-HA is additive
or synergistic, the combination index method was used (209). The concentration at
which 50% of the effect is reached (IC50) and the slope parameter (m) for each agent
alone and in combination (at a ratio of 1:1) were determined from the median-effect plot,
a linear relationship plotting log(D) versus log(fa/fu) based on Chou’s median-effect
equation:
fa/fu = (D/Dm)m
where D is the dose (concentration) of the drug, Dm is the IC50 as determined from the
x-intercept of the median-effect plot, fa is the fraction of cells affected, fu is the fraction of
cells unaffected (fu=1-fa), and m is an exponent signifying the steepness for the sigmoid
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dose-effect curve. A combination index (CI) was then calculated to assess synergism,
additivity, or antagonism according to the following equation:
CI = (D)1/(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2
where (D)1 and (D)2 are the concentrations of ZDV and SMX-HA which combined
produce x% cytotoxicity, and (Dx)1 and (Dx)2 are the concentrations of each drug which
alone produce x% cytotoxicity. The equation assumes independent mechanisms of
drug action between the agents. CI=1 indicates an additive interaction, CI<1 indicates
synergy between the two drugs, and CI>1 indicates antagonism (209).

Apoptosis inhibition
The pan-caspase inhibitor Z-VAD-FMK was utilized to inhibit apoptosis associated
with ZDV plus SMX-TMP exposure in cultured B lymphocytes. Increasing
concentrations of ZDV (72-hour exposure) and SMX-HA (1- to 2-hour exposure) were
used to induce apoptosis, with Z-VAD-FMK 20μM added 15 minutes prior to SMX-HA in
an attempt to block apoptotic mechanisms that utilize caspases. Etoposide was used
as a positive control to induce mitochondrial pathway apoptosis that is caspasedependent, through the inhibition of topoisomerase II, which causes DNA strand
breakage and arrest in late S or early G2 stages of the cell cycle. Cells were incubated
with etoposide at an optimal concentration of 20μg/ml for 4 hours with and without ZVAD-FMK.

RNase protection assay
RNA was isolated from cells cultured in the presence of 10μM ZDV (72 hours) and/or
10μM SMX-HA (8 hours) using TRIzol® reagent (Invitrogen, Carlsbad, CA). RNase
protection assay was performed using the BD Riboquant™ RPA kit (BD Pharmingen,
San Diego, CA) using the mAPO Multiprobe Template (BD Pharmingen) according to
the manufacturer’s instruction. Briefly, the RNA probe was synthesized using T7 RNA
polymerase in the presence of ATP, GTP, UTP and CTP supplemented with [α32

P]UTP. Approximately 3.6x105 cpm of 32P-labeled probe was hybridized to RNA pools
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from each sample at 560C overnight, followed by digestion with RNase T1/A for 15
minutes at 370C. The protected RNA fragments were precipitated and then separated
on a 4.75% acrylamide gel, and imaged by autoradiography. Band density for each
mRNA encoding for caspases-8, -3, -6, -11, -2, -7, and -1 were calculated and
compared to band density from the 2 housekeeping gene products, L32 and GAPDH.

HPLC
Serum SMX concentrations were determined 18 hours after drug dosing by HPLC as
previously described (210). Briefly, 50µl of each serum sample was mixed with caffeine
(20µg/ml) as an internal standard. The drugs were extracted with 400µl acetonitrile,
vortexed, and purified by centrifugation for 10 minutes. The supernatants were then
collected and evaporated under nitrogen gas, and resuspended in 50µl of mobile phase
containing a v/v ratio of 80:20:1:0.5 deionized water, acetonitrile, acetic acid, and
triethylamine. Using a Shimadzu HPLC system (Kyoto, Japan), 10µl of sample was
injected onto a Nova-pak C18 10cm x 5mm Z module solid phase column (Waters
Corporation, Milford, MA) at a flow rate of 1ml/min. UV absorbance detection at 254nm
was performed with a SMX retention time of 12.1 minutes and an internal standard
retention time of 3.5 minutes. The accuracy of quality control samples based on
percent difference ranged from 2.3 to 18.1 percent and the overall coefficient of
variance was 0.056. The standard curve peak area ratio SMX to internal standard was
linear over a range of 5µg/ml to 1000µg/ml (r2 = 0.9866).

Mrp1 mutation experiments
Mrp1 Targeted Mutation Mice were purchased from Taconic (Germantown, NY)
along with gender-and age-matched FVB/N background controls. The mrp1 gene
encodes for the ATP-binding cassette, subfamily C, member 1A protein, commonly
know as the multidrug resistance protein-1 (Mrp1). This mutation renders mice deficient
in functional Mrp1. This protein is responsible for the cellular excretion of many drugs,
GSH, and GSH-drug complexes (211). Deficiency in this protein causes a significant
decrease in GSH and GSH-conjugated substrate efflux, and increases cell sensitivity to
many chemotherapeutic agents (211). These Mrp1 functional knockout mice (Mrp1-/-)
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and background-matched controls (FVB/N) were dosed with ZDV plus SMX-TMP or
vehicle control via oral gavage for 14 days as described in detail in Chapter 2. Mice
were humanely killed and bone marrow was isolated as described above, and analyzed
for apoptosis, and for B-lineage cell phenotype populations as outlined in Chapter 2.
Bone marrow cells from drug-naïve mice were also placed into culture as previously
described.

Statistical analysis
All cell numbers and percentages were compared using one-way ANOVA followed
by the Student-Neuman-Keul test for ad hoc pair-wise comparisons evaluating each
treatment group compared to its corresponding control, using commercially available
software (Sigmastat, SPSS, Chicago, IL). Data that failed normality testing was
compared using the Kruskal-Wallis One Way Analysis of Variance on Ranks method
(Figure 3.8B). Results were determined to be statistically significant when a p-value <
0.05 was obtained. Data are expressed as the mean +/- standard deviation.

C. RESULTS

Concentration-dependent cytotoxicity increases with increasing SMX metabolite
concentrations
Concentration-dependent cytotoxicity was observed in bone marrow culture after 24
hour incubation with SMX-NO and SMX-HA, with SMX-HA causing a more potent
toxicity than SMX-NO (Figure 3.2). As concentrations of SMX metabolites increased in
the presence of 1 and 10μM ZDV, viable percentages (annexin-V negative, PI negative)
of B lymphocytes decreased (Figure 3.2A). Maximum toxicity with SMX-HA occurred
at the 100μM concentration at 24 hours, and substantial toxicity was not demonstrated
with SMX-NO until the 40μM concentration was reached. Percentage of apoptotic cells
(annexin-V positive, PI negative) increased as concentrations of SMX metabolites
increased, but at the highest concentration (500μM), the percentages of apoptotic cells
were diminished, likely due to low percentages of viable cells remaining (Figure 3.2B).
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Figure 3.2 Concentration-dependent cytotoxicity in 24 culture. Mouse bone marrow
was isolated and cultured at 1x106 cells per well in 24-well culture tissue culture plates
with IL-7 at 25U/ml to stimulate B cell proliferation as detailed in Materials and Methods.
ZDV at 1 and 10μM concentrations, and SMX-HA or SMX-NO at concentrations
between 10 and 500μM were added to corresponding wells, and the cells were
incubated for 24 hours. Cells were harvested, stained with B220, annexin-V, and PI as
described, and analyzed by flow cytometry. Panel A shows percentage of cells that
were viable (annexin-V negative, PI negative) at each concentration combination, and
panel B depicts percentage of cells that were apoptotic (annexin-V positive, PI
negative). Data is representative of multiple trials.

Importantly, the presence of ZDV at concentrations of 1 and 10μM did not contribute to
the toxicity with 24 hours of incubation, as the viability and apoptosis curves at different
ZDV concentrations were virtually identical.

Absence of the reducing agent 2-ME, and the addition of TMP to culture,
increased cytotoxicity
Because the toxic metabolites of SMX are oxidative species, and it has been shown
that reducing agents limit their toxicity, a series of experiments was performed analyzing
the contribution of 2-ME, a powerful reduction species present in our culture system, to
the overall toxicity of ZDV and SMX metabolites to B cells. Figure 3.3A shows that the
toxicity to B lymphocytes is increased when 2-ME is removed from cell culture in the
presence of ZDV and SMX-NO or SMX-HA. When comparing cell viability to panel A in
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Figure 4.2, the toxicity is decreased from approximately 90% at lower SMX metabolite
concentrations, to approximately 40 to 60% in the absence of 2-ME.
Figure 3.3B depicts the cytotoxicity resultant from the addition of TMP to the culture
system along with ZDV and SMX metabolites (again in the absence of 2-ME). Viable
cell percentages are shown, and the addition of TMP increased cytotoxicity among B
cells in culture, reducing viability to approximately 20-30% at the lower SMX-HA
concentrations.
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Figure 3.3 Absence of 2-ME, addition of TMP increase toxic effects. Mouse bone
marrow was isolated and cultured at 1x106 cells per well in 24-well culture tissue culture
plates with IL-7 at 25U/ml to stimulate B cell proliferation as detailed in Materials and
Methods, except in these experiments, 2-ME was omitted from the culture medium.
ZDV at 10 and 100μM concentrations, TMP at 1 and 10μM (panel B), and SMX-HA or
SMX-NO at concentrations between 10 and 500μM were added to corresponding wells,
and the cells were incubated for 24 hours. Cells were harvested, stained with B220,
annexin-V, and PI as described, and analyzed by flow cytometry. Data depicts
percentage of B cells viable (annexin-v negative, PI negative) (A) with SMX metabolite
and ZDV exposure, and (B) when TMP is also added along with SMX-HA and ZDV.
Graphs are representative of one trial only.

ZDV contributes to cytotoxicity when exposure is lengthened to 72 hours

Mouse bone marrow was again cultured along with IL-7 and 2-ME, with the addition
of ZDV and SMX-HA to the culture medium. In this set of experiments, ZDV exposure
(10 and 100μM) was lengthened to 72 hours. SMX-HA, at increasing concentrations,
was added to the cells for the final 18 hours of incubation time. Upon harvest and
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analysis by trypan blue staining and flow cytometry, cytotoxicity increased with
increasing ZDV concentrations. In Figure 3.4, panels A and B depict total cell and B cell
viable percentages, respectively, over increasing SMX-HA concentrations for ZDV 0,
10, and 100μM series. As ZDV concentration increased, cytotoxicity increased. Panel
C shows the total number of cells that were viable that correspond to the percentages in
Figure 3.4A. In panel D, the percentages of B cells that were apoptotic are shown as a
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Figure 3.4 ZDV cytotoxicity with 72 hours incubation. Mouse bone marrow was
isolated and cultured at 1x106 cells per well in 24-well culture tissue culture plates with
IL-7 at 25U/ml to stimulate B cell proliferation as detailed in Materials and Methods.
ZDV at 0, 10, and 100μM concentrations was incubated with the cells for 72 hours, and
SMX-HA was added to the appropriate wells at concentrations between 10 and 500μM
for the final 18 hours of incubation. Cells were harvested, stained with B220, annexinV, and PI as described, and analyzed by flow cytometry. Viability was also determined
for the total cell population by trypan blue staining. Data depicts percentages of (A)
total cells and (B) B cells viable after drug exposure. Panel C represents the total
number of viable cells in culture, and panel D represents the percentage of B cells that
were apoptotic (annexin-V positive, PI negative). Data are representative of multiple
trials.
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function of increasing SMX-HA concentration. The percentages of apoptotic cells fall
with increasing concentrations of SMX-HA because most cells are already dead at the
higher concentrations.

Cytotoxicity in vitro is synergistic

When culture conditions were determined to produce an induction of cytotoxicity with
each drug and in combination (see above), we analyzed the data generated to assess
synergy. The median-effect combination index method was used to calculate CI values.
CI=1 was defined by Chou and Talalay as signifying an additive effect. CI<1 indicates
synergy between 2 agents, and CI>1 indicates antagonism. CI values were calculated
for dose effect levels based on levels of cell death of 25, 50, and 75%. Parameters
used to calculate CI were derived from dose-response curves generated for ZDV alone,
SMX-HA alone, and the combination of both drugs used at a ratio of 1:1. Cells were
cultured in the presence of IL-7 at 1x106 cells/ml per well as described and over
incubation times for ZDV and SMX-HA of 72 hours and 24 hours, respectively.
Concentrations ranged from 1 to 100μM for ZDV, and from 10 to 100μM for SMX-HA.
Table 3.1 shows the IC values at the various levels of cell death, along with the
Table 3.1 Combination index values for synergy.
Agent

CI value cell death induction, IC(x)
IC25

IC50

IC75

Parameters
Dm(uM)

m

r

ZDV

61.1

0.56

0.91

SMX-HA

51.9

0.48

0.93

8.17

0.39

1.00

Combination

0.16

0.31

0.63

Interaction

synergy

synergy

synergy

Combination index values calculated at various levels of cytotoxicity of total bone
marrow cells treated with the combination of ZDV and SMX-HA. CI=1 indicates
additivity, CI<1 indicates synergy, and CI>1 indicates antagonism. IC(x)=concentration
at which cell death is induced by x%. Dm=median-effect dose (IC50), m=slope
parameter, and r=correlation coefficient of median-effect plot. Data is representative of
multiple experiments.

52

parameters from the median-effect plots. The cytotoxic effect of the 2 drugs in
combination is synergistic to bone marrow cells in vitro.

Most apoptotic cells arise from the S/G2/M phases

To further explore how cell cycle affects relate to apoptosis with ZDV plus SMX-TMP
exposure, we designed a series of experiments to investigate from which stages of the
cell cycle cells were becoming apoptotic. Mouse bone marrow cells were either
incubated for 20 hours with 1mM hydrocortisone, or with ZDV 10μM for 72 hours with
SMX-HA 20μM added for the final 24 hours. These doses were chosen based upon the
data presented in Figure 3.4, due to the high percentage of apoptotic cells at this dosing
combination.
Cells were analyzed for apoptosis via the Tunel assay while simultaneously stained
with PI. The data is displayed in Figure 3.5. Panels A and B are representative dot
plots for cells exposed to hydrocortisone (A) and ZDV plus SMX-HA (B). Regions
indicate cells in the G0/G1 interval of the corresponding cell cycle histograms. It is
evident that the majority of cells that are apoptotic (BrdU-FITC positive) arise from the
S/G2/M phases as a result of ZDV plus SMX-HA exposure (panel B). Comparatively,
hydrocortisone treatment causes cells to undergo apoptosis in a cell-cycle non-specific
manner, as the apoptotic cell proportions are similar to overall cell cycle proportions
(panel A). Panel D shows the percentages of total cells that were in G0/G1 phases, in
S phase, and the percentage of total cells that were simultaneously in S/G2/M phases
and apoptotic. This data demonstrates that ZDV plus SMX-TMP exposure is causing
cells to initiate the apoptotic process from these phases, and that cells are sequestered
in the S phase, with a simultaneous depletion of cells reaching G0/G1. Statisticallysignificant differences were not reached because only 2 wells were used per
experiment.

Addition of a pan-caspase inhibitor did not alter apoptosis induction

Mouse bone marrow was again cultured as above, along with ZDV at 100μM for 72
hours, with the addition of SMX-HA for the final 1 or 2 hours of incubation. The pancaspase inhibitor Z-VAD-FMK at a concentration of 20μM was added to the appropriate
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Figure 3.5 Relationship between apoptosis and cell cycle. Bone marrow cells were
obtained from normal BALB/c mice and placed into culture with IL-7 at 1x106 cells/ml
per well as described in Materials and Methods. Cells were either incubated for 20
hours with 1mM hydrocortisone, or with ZDV 10μM for 72 hours plus SMX-HA 20μM for
the final 24 hours. Cells were harvested and analyzed via the Tunel assay while
simultaneously stained with PI. Panels A and B display flow cytometry output from
representative dot plots for cells exposed to hydrocortisone (A) and ZDV plus SMX-HA
(B). Regions indicate cells in the G0/G1 interval of the corresponding cell cycle
histograms. Panel C shows the percentage of total cells that were in G0/G1 phases, in
S phase, and the percentage of total cells that were concurrently in S/G2/M phases and
apoptotic. Data represents mean percentages for 2 wells per group, and are
representative of multiple repetitions. Differences were not statistically significant for p
< 0.05.

wells 15 minutes before the SMX-HA. Figure 3.6 shows that as SMX-HA
concentrations increase, apoptosis increases. Z-VAD-FMK did not significantly
decrease this apoptotic effect at any concentration, or at either timepoint. The
etoposide-exposed cells served as a positive control, showing that Z-VAD-FMK
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Figure 3.6 Caspase inhibition and apoptosis. Mouse bone marrow was isolated and
cultured at 1x106 cells per well in 24-well culture tissue culture plates with IL-7 at 25U/ml
to stimulate B cell proliferation as detailed in Materials and Methods. ZDV at 100μM
was incubated with the cells for 72 hours, and SMX-HA was added to the appropriate
wells at 10 and 100μM concentrations for the final 1 or 2 hours of incubation, as
indicated. The pan-caspase inhibitor Z-VAD-FMK at 20μM was added to half of the
wells 15 minutes prior to the addition of SMX-HA. Cells were harvested and stained for
apoptosis with annexin-V and PI as described, and analyzed by flow cytometry. Cells
were gated on lymphocytes and the percentages apoptotic (annexin-V positive, PI
negative) are reported. Etoposide 20ug/ml was used as a positive control to induce
apoptosis (4 hour incubation). Each bar represents triplicate wells. A statisticallysignificant reduction in apoptosis (*) by the addition of Z-VAD-FMK was defined at p <
0.05.

mRNA of initiator and effector caspases is not up-regulated in the presence of
combination drug exposure

Bone marrow isolated from normal mice was once again placed into culture as
described above for 72 hours with 10μM ZDV added to 50% of the wells. For the final 8
hours, SMX-HA was added at a concentration of 10μM to the appropriate wells to
generate cells that were exposed to ZDV, SMX-HA, both drugs, or neither. At the end
of the incubation, cells were harvested and RNA was isolated with TRIzol Reagent.
RPA was performed as described to ascertain relative message of genes encoding
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signaling and effector caspases. Data comparing the mRNA expression to the
housekeeping genes L32 and GAPDH are presented in Figure 3.7. Combination
exposure did not increase the relative expression of any caspases tested. The cells
that were exposed only to SMX-HA had moderate increases in relative message levels
of caspase-8, caspase-3, and caspase-2. This experiment has not been repeated and
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Figure 3.7 Message expression for signaling and effector caspases. Bone marrow
isolated from normal mice was cultured as described for 72 hours with 10μM ZDV
added to 50% of the wells. For the final 8 hours, SMX-HA was added at a concentration
of 10μM to the appropriate wells to generate cells that were exposed to ZDV, SMX-HA,
both drugs, or neither (control). RNA was isolated with TRIzol Reagent. RPA was
performed as described using the mAPO Multiprobe template to ascertain relative
expression of genes encoding caspase-8, caspase-3, caspase-6, caspase-11, caspase2, caspase-7, and caspase-1. Expression of mRNA relative to the housekeeping genes
L32 and GAPDH were plotted. Data is representative of a single experiment.
received ZDV plus SMX-TMP versus mice that received only SMX-TMP.

56

SMX steady-state serum concentrations were increased with ZDV exposure

To investigate whether there was a systemic pharmacokinetic effect on drug
disposition, SMX serum concentrations were compared between mice that
Mean SMX serum concentrations for these groups of mice are shown in Figure 3.7A.
Samples are indicative of drug concentrations 18 hours after the 28th daily doses of
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Figure 3.8 SMX serum concentrations. SMX serum concentrations increased in mice
when also exposed to ZDV. Normal BALB/c mice were dosed for 28 days with SMXTMP (840mg/kg SMX and 160mg/kg TMP) with or without ZDV (240mg/kg) daily via
oral gavage. Mice were humanely killed after 28-days dosing, 18 hours after the final
dose of each drug, and serum was collected. SMX concentration was determined by
HPLC as detailed in Materials and Methods (panel A). Panel B shows the standard
curve generated using the peak height ratio with the internal standard. Panel C is a
representative chromatogram from a mouse in the SMX-TMP group, showing the
internal standard peak (3.542 minute retention time) and the SMX peak (12.083 minute
retention time). Significant difference to control group (*) was defined at an alpha level
of < 0.05. Data represents 5 mice per treatment group, and representative of 2
separate experiments.
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The mean SMX concentration in the combination treatment group was 95.4 ± 13.5
μg/ml, which was significantly higher than the mean SMX concentration in the SMX only

group (46.4 ± 33.5 μg/ml). Figure 3.8B illustrates the standard concentrations curve
used to calculate sample concentrations, with an r2 value relating SMX concentration to
peak height ratio of SMX to the internal standard of 0.9866. Panel C of Figure 3.8 is a
representative chromatogram showing the internal standard peak (3.542 minute
retention) and SMX peak (12.083 minute retention).
Mrp1-/- mice

One hypothesis to explain the altered disposition of SMX by ZDV concerns the upregulation of Mrp4 by ZDV (discussed above). Because of the availability of Mrp1-/mice, and because Mrp1 has the same function of GSH and GSH-substrate efflux as
does Mrp4, we decided to test whether the absence of Mrp1 had any effect on SMX
toxicity. Figure 3.9A represents data collected after bone marrow cells from Mrp1-/- and
FVB/N background control mice were incubated in the presence of SMX-HA for 24
hours. Although no statistics could be performed, there was a slight decrease in the
percentage of viable cells in the Mrp1-/- animals versus the control mice, as well as a
slight increase in percentage of dead cells at each concentration combination. The
percentages of apoptotic cells were virtually identical between the two strains (Figure
3.9A).
We then dosed mice of both phenotypes as described above with either the
combination of ZDV and SMX-TMP, or neither drug for a period of 14 days. Figure 3.8B
depicts percentages of dead B220+ B cells and apoptotic B220+ B cells harvested from
the bone marrow of Mrp1-/- and background control mice. Of importance, only 2 of the 5
Mrp1-/- mice dosed with ZDV plus SMX-TMP survived until time of sacrifice. The
percentages of dead cells (annexin-V positive, PI positive) and apoptotic cells (annexinV positive, PI negative) in the combination treatment mice were only significantly
increased in the background control mice. The Mrp1-/- mice show a trend toward an
increase in dead and apoptotic B cell percentages, but the data is not statistically
significant.
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Figure 3.9 Mrp1-/- mice display similar toxicity as background controls. Mouse bone
marrow was isolated from Mrp1-/- and background matched FVB/N mice as described.
Cells were cultured at 1x106 cells per well in 24-well culture tissue culture plates with IL7 at 25U/ml to stimulate B cell proliferation as detailed in Materials and Methods. SMXHA was incubated with the cells for 24 hours, and cells were harvested and stained for
CD19, annexin-V, and PI and analyzed for apoptosis via flow cytometry. Panel A shows
percentages of bone marrow B cells that are either viable (annexin-V negative, PI
negative), dead (annexin-V positive, PI positive), or apoptotic (annexin-V positive, PI
negative) for each mouse strain for increasing SMX-HA concentrations. In addition,
Mrp1-/- and FVB/N mice were dosed in vivo for 14 days with either ZDV plus SMX-TMP
or control vehicle daily via oral gavage, and the bone marrow was harvested. Panel B
shows the percentage of cells in the bone marrow that were either dead (annexin-V
positive, PI positive) or apoptotic (annexin-V positive, PI negative). Panel C illustrates
the numbers of B-lineage cells after 14 days of dosing discerned by flow cytometry in
both mouse strains and both treatment groups, including pre-pro-B, pro-B, and late preB cells. The early pre-B cell subtype populations are expressed on panel D due to the
smaller scale needed. Differences of statistical significance (*) from control were
defined at a p-value of < 0.05. Data in panels B-D are mean ± SD, representative of
one experiment only, with 2-5 mice per group.
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Upon examination of B-lineage subtypes in the bone marrow, pre-pro-B, pro-B, and
late pre-B cell numbers were similarly depleted in both mouse strains by combination
drug treatment (Figure 3.9C). Differences were statistically significant in the FVB/N
background control mice, but not in the Mrp1-/- strains, due to the fact that only 2 mice
lived to the time of sacrifice in the combination therapy group of the Mrp1-/- mice. Early
pre-B cell numbers, although depleted to a degree in the combination-treated groups in
both mouse strains, did not reach statistically-significant differences (Figure 3.9D).
These results should be considered preliminary since these in vivo experiments have
not been repeated.

D. CONCLUSIONS

While this chapter contains much data that is preliminary in nature, many aspects of
the combination toxicity concerning ZDV and SMX-TMP have been addressed. These
data have laid a foundation for further investigation into the mechanism of this toxicity.
ZDV and SMX metabolites both cause concentration-dependent toxicity to IL-7
dependent B cell populations in our in vitro model. We confirmed the fact that SMX-HA
is more toxic than SMX-NO here in B cells, as has been shown in the literature to be the
case in lymphocytes and neutrophils (152). We were unable to demonstrate
contributions of ZDV to the toxicity with 24 hours exposure; its effects were contributory
only when exposure time was extended to 72 hours. Synergy was then demonstrated
at doses ranging from IC25 to IC75. Future work to determine synergy in vivo would be
contributory to this study. The steady-state concentrations obtained for SMX in patients
also receiving ZDV increased to over the IC50 of SMX from the in vitro data. The
significance of this is yet to be determined.
It is known that the toxicity of the oxidative metabolites of SMX can be diminished by
the presence of reducing agents, such as GSH. Here, we have shown that the
combination toxicity is also decreased by the presence of 2-ME in the culture medium.
When it was removed, cell viability was much lower as a result of drug exposure at
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corresponding concentrations of ZDV and SMX metabolites. The removal of 2-ME is
expected to lower the baseline viability rate in any culture system.
Apoptosis is also confirmed in this chapter by a second method of measurement, the
Tunel assay. Figure 3.5 demonstrates that cells are selectively entering the apoptotic
state from the S/G2/M phases of the cell cycle. This confirms the data from our in vivo
trials indicating that cells are being sequestered in these proliferative phases in the early
pre-B cell population. The evidence that cells are entering apoptosis from selected
phases strengthens the argument that this is a cell-cycle specific effect.
Apoptosis can be caused by the presence or absence of a variety of stimuli, but most
often the intracellular signaling pathways utilize caspases to carry out the apoptotic
process. Whether the initiation is mediated through death receptors on the cell surface,
or through the mitochondrial pathways, several caspases are activated to signal an
apoptotic death. It appears that B cells in our culture system are undergoing a caspaseindependent apoptosis as a result of ZDV plus SMX-HA treatment. Refer to Chapter 6
for an in-depth discussion.
The addition of the pan-caspase inhibitor Z-VAD-FMK did not diminish the
percentage of cells in the apoptotic phase as a result of combination drug exposure.
This is shown in Figure 3.6 for cells incubated with ZDV 100μM for 72 hours and SMXHA at 10 and 100μM for the final 1 or 2 hours. This short incubation was the optimal
time to test, as apoptosis occurs quickly upon SMX-HA exposure when cells have been
in the presence of ZDV for an extended period. Of note, the aldehyde-based caspase-3
inhibitor Ac-Asp-Met-Gln-Asp-CHO (Ac-DMQD-CHO) was also used in many
experiments in an attempt to inhibit apoptosis as a result of drug exposure. Although it
was never effective in diminishing the apoptotic effect, an appropriate positive control
was never established, so the data was not presented.
This caspase-independent mechanism of apoptosis is also supported by the RPA
data presented in Figure 3.7. Combination drug exposure did not alter the relative
message levels of any caspases tested. Although message was slightly increased in
the SMX-HA exposure group of caspases 8, 3, and 2, we cannot draw any conclusions
from this data, because of a lack of confirmatory trials. See Chapter 1 for a detailed
discussion of apoptosis.
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The steady-state SMX concentration in the serum is increased in mice receiving
concurrent ZDV treatment. The 28-day data shown in Figure 3.8 was also confirmed by
data generated after 21 days of dosing. This is a significant piece of information with
regards to the mechanism of combined toxicity. This is a foundation for further study.
The SMX concentration was increased from approximately 50μg/ml to 100μg/ml. This
corresponds to a molar increase from approximately 200μM to a level of 400μM. When
comparing these ranges to our in vitro studies, this increase is within the concentration
range tested, that showed a dose-dependent increase in toxicity. However, both
concentrations are in the range in which toxicity was at its maximum. How this
corresponds to concentrations obtained in the bone marrow is unknown.
If GSH efflux is involved in this drug-drug interaction, the in vitro data obtained using
Mrp1-/- mice support the hypothesis that ZDV competitively inhibits the transport of
SMX-HA-GSH complexes, thereby increasing the SMX-HA concentrations inside the
cells. This would increase the sensitivity of bone marrow cells from the Mrp1-/- mice,
which was seen slightly in Figure 3.9A. While there is a slight increase in toxicity in
vitro, the in vivo dosing data in Figure 3.9 shows that the absence of Mrp1 may be

protective. This, despite the fact that 3 of the 5 Mrp1-/- mice dosed with ZDV plus SMXTMP died. The cause of death in the mice that died is unknown. These results do not
take into account other mechanisms of GSH and GSH-substrate efflux that could be
compensating for the lack of transport from Mrp1. Clearly, further study is needed to
determine the role of Mrp transporters in this context.
Because we find the toxicity of this combination to be concentration (or dose) dependent, this data raises the concern of the potential clinical significance of this
interaction. It is difficult to determine allometrically the proper dose to give to mice to
mimic human drug exposure, especially to generate comparable exposure to sites that
have unknown drug concentrations, such as the bone marrow. The next step taken was
to investigate the effect of combination drug exposure on the immune response in mice
challenged with an infectious agent, which will be presented in Chapter 4.

Copyright © David James Feola 2005
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CHAPTER 4: Impact on host response

A. OVERVIEW

The previous chapters demonstrate that ZDV plus SMX-TMP exposure decreases
immune cell populations in the bone marrow of normal mice due to apoptosis induction.
Our next goal was to investigate whether the effects of this drug toxicity have an impact
on host response. To determine this, BALB/c mice were exposed to each drug
separately or in combination as described. On day 4 after dosing completion, mice
were infected intratracheally with Pneumocystis murina. This infection model was
utilized to investigate cellular and humoral immune responses in these mice as a result
of combination drug exposure.
PCP continues to be one of the most common AIDS defining illnesses (212, 213).
The Centers for Disease Control and Prevention recommend clinicians to prophylax for
PCP when HIV-infected individuals have CD4+ T lymphocyte counts of less than 200
cells/μl (214). The drug of choice for the prophylaxis and treatment of this fungal
infection is SMX-TMP, which has been shown to improve survival rates among patients
with HIV (214). SMX and TMP are used in combination to potentiate their inhibition of
folate synthesis and increase activity against Pneumocystis, as well as many
susceptible bacteria.
Components of adaptive immune function that are necessary in the clearance of
Pneumocystis murina from mice have been thoroughly studied. Mice that lack

functional CD4+ T cells have an inability to mount an effective response to
Pneumocystis (215, 216). In addition, mice that lack functional B lymphocytes have

been shown to also be highly susceptible to Pneumocystis infection (217-219).
Because B cells are depleted from the bone marrow of mice that receive ZDV and SMXTMP, we used this infection model to assess the impact of drug toxicity upon host
response to an opportunistic pathogen.
Our hypothesis was that exposure to ZDV plus SMX-TMP would alter the humoral
immune response to pulmonary Pneumocystis infection in normal mice, and the
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clearance of Pneumocystis would be delayed. The aims of this chapter were 1) to
evaluate the cellular host response to Pneumocystis in the lungs and draining lymph
nodes, 2) to compare Pneumocystis-specific antibody responses between groups, and
3) to evaluate Pneumocystis clearance profiles among drug dosing groups. An
additional aim in this series of experiments was to characterize the recovery of Blineage populations in the bone marrow after drug discontinuation.
Immune cell populations (in lung digest and bronchial alveolar lavage fluid (BALF),
and tracheobronchial lymph nodes (TBLN)), lung Pneumocystis burden, and serum
Pneumocystis-specific antibody titers were determined at post-infection timepoints. The

result of combination drug exposure was primarily manifested in the B cell response in
the TBLN, resulting in a lower Pneumocystis-specific antibody titer in the serum. The
overall effect did not significantly change Pneumocystis clearance, although there was a
trend of a delayed clearance in the combination treated animals.

B. MATERIALS AND METHODS

Mice and experimental design

Four- to six-week old BALB/c mice were obtained from NCI (Indianapolis, IN) and
quarantined for at least 7 days before manipulation. C.B-17 severe combined
immunodeficient mice (SCID), originally from Taconic (Germantown, NY), were bred in
our facility and used to maintain a source of Pneumocystis. Mice were housed in the
Veterans Administration Veterinary Medical Unit under pathogen free conditions with a
12 hour light/dark photocycle and food and water both freely available. All experiments
and procedures were approved by the Veterans Administration Institutional Animal Care
and Use Committee.
ZDV (3’-azido-3-deoxythymidine), TMP (2,4-diamino-5-[3,4,5-trimethoxybenzyl]pyrimidine), SMX (4-amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide) were
purchased from Sigma-Aldrich (St. Louis, MO). Drug doses were prepared daily by
weighing each powder form into polypropylene tubes, SMX and TMP together, and ZDV
separately, and suspending each in its appropriate vehicle: ZDV dissolved into sterile-
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filtered deionized water to a concentration of 50mg/ml, SMX and TMP suspended in
0.5% methylcellulose at concentrations of 106mg/ml and 8mg/ml, respectively. Mice
were randomized into four treatment groups, either receiving ZDV or SMX-TMP alone,
in combination, or vehicle only (control), at the following doses based on an
approximate mean mouse weight of 20 grams: ZDV 240mg/kg (5mg per mouse), SMX
840mg/kg (16mg per mouse), and TMP 160mg/kg (1.2mg per mouse). Each mouse
received two doses daily, either with drug or vehicle. Doses were given via oral gavage
with an 18-gauge blunt-tipped dosing needle.

Pneumocystis infection

Lungs from Pneumocystis-infected immunodeficient mice were excised and pushed
through steel mesh in Hank’s Balanced Salt Solution (HBSS). Aliquots were spun onto
glass slides, fixed in methanol, and stained with Diff-Quik (Dade Behring Incorporated,
Newark, DE). Pneumocystis was enumerated microscopically as described below (215,
220, 221). Mice were infected intratracheally under halothane anesthesia with 107
Pneumocystis organisms 4 days after discontinuation of drug dosing. Mice were then

humanely killed at various timepoints post-infection for analysis.

Tissue processing and Pneumocystis enumeration

Lungs were lavaged by tracheal cannulation under deep halothane anesthesia with 5
washes performed with 1ml HBSS containing 3mM ethylenediaminetetraacetic acid
(EDTA). Lungs were minced and digested by incubation with 50 U/ml DNase and
1mg/ml collagenase A and pushed through mesh to form single cell suspensions.
TBLN were excised into HBSS and pushed through mesh to create single cell
suspensions. Bone marrow was flushed from femurs and tibias into RPMI-1640 plus
5% fetal calf serum, and single cell suspensions were obtained via passage through a
25-gauge needle. Red blood cells in all samples were lysed with hypotonic buffer
consisting of 8.24g/l ammonium chloride, 1g/l potassium bicarbonate, and 37.2mg/l
EDTA. Cells were then washed, enumerated, and transferred into 5ml round-bottom
polystyrene tubes for phenotyping via flow cytometry. Lung digest aliquots were diluted
to 1:20 and 100μl was spun into a 28.3 mm2 area on glass slides using a cytocentrifuge,
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then fixed with methanol and stained with Diff-Quick staining solutions. Pneumocystis
nuclei were enumerated microscopically by counting the number of nuclei per 20-50 oil
emersion fields. This number was used to calculate the total number of nuclei per lung
(215, 220, 221). Slides from the mice were counted in a randomized, blinded fashion.
The limit of detection of Pneumocystis was log10 3.23.
Cell phenotyping

Splenocytes, BALF cells, and lung digest cells were incubated with the appropriate
concentrations of fluorescently-labeled monoclonal antibodies (mAb) specific to murine
T cells (CD4, CD8, CD44, and CD62L) and B cells (CD19, CD80 and CD86). Activated
CD4+ and CD8+ T cells were defined as the CD44hi/CD62Llo phenotype, and B cells
were considered activated if either CD80 or CD86 was up-regulated. Bone marrow
cells were incubated with 2 separate panels of fluorescently-labeled mAb for
phenotyping B lineage cells. Antibodies were purchased from BD Biosciences
Pharmingen, San Diego, CA or eBiosciences San Diego, CA. These panels were 1)
IgM, CD43, and B220; and 2) CD43, B220, BP-1, and heat stable antigen (HSA).
Subpopulations delineated included pre-pro-B, pro-B, early pre-B, and late pre-B cells
according to B lineage subgroups as described by Hardy et. al. (178). Cells were
washed before and after staining with Dulbecco’s Phosphate Buffered Saline containing
0.1% bovine serum albumin and 0.02% sodium azide. All cells were analyzed for
phenotype by flow cytometric multiparameter analysis using a FACSCaliber Flow
Cytometer (BD Biosciences, Mountain View, CA) and analyzed using WinList software
package (Verity Software House, Topsham, ME). Greater than 50 thousand events
were routinely examined.

Apoptosis analysis

Cells were determined to be in the process of an apoptotic cell death by using the
annexin-V binding protocol with propidium iodide (PI) exclusion kit according to the
manufacturers instructions (BD Biosciences Pharmingen). Samples were analyzed by
flow cytometry as above, and cells that fluoresced annexin-V positive/PI negative were
considered apoptotic.
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Pneumocystis-specific enzyme linked immunosorbent assay (ELISA)

Specific antibodies to Pneumocystis antigens were measured in the serum of mice at
each timepoint as previously described (221). Blood was collected from the abdominal
aorta, and sera were isolated by centrifugation and frozen at -800C until time of
analysis. 96-well microtiter plates were coated with sonicated Pneumocystis (10µg/ml)
for 2 hours, and coated plates were blocked with 5% dry milk in HBSS supplemented
with 0.05% Tween 20 for 1 hour. Test sera were diluted serially from 1:50 to 1:1600
and incubated in the plates overnight at 40C. Plates were extensively washed, and
bound antibodies were detected by using anti-IgG and anti-IgM secondary antibodies
conjugated to alkaline phosphatase. After 4 hours at 370C, plates were washed and
developed by using p-nitrophenylphosphate (1 mg/ml) in diethanolamine buffer and
read at 405nm. The endpoint dilutions at which the optical density at 405nm dropped
below 0.1 are reported.

Statistical analysis

All cell numbers, Pneumocystis counts, and antibody titers in the drug exposure
groups were compared to the control group using one-way ANOVA followed by the
Student-Neuman-Keul test for ad hoc pair-wise comparisons using commercially
available software (Sigmastat, SPSS, Chicago, IL). Data that failed normality testing
was compared using the Kruskal-Wallis One Way Analysis of Variance on Ranks
method. Results were determined to be statistically significant when a p-value < 0.05
was obtained. Data are expressed as the mean ± standard deviation.

C. RESULTS

Combination dosing increased sensitivity to Pneumocystis inoculation

Day to day subjective observation of the mice showed an increase in lethargy, failure
to groom, hunched appearance, and an overall decrease in health in the ZDV plus
SMX-TMP group as compared to the other groups, becoming marked by approximately
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day 7 of dosing. During all infection experiments conducted, six out of a total of 24 mice
in the combination treatment groups died after being infected with Pneumocystis. The
median time to death was 4 days, with a range of 1 to 7 days post-infection. Out of all
infection experiments completed, one of 24 mice in the control group died (1 day after
inoculation), whereas all mice dosed in the single drug groups survived until time of
sacrifice. Only mice that survived to the scheduled timepoints were included in the
analyses.

B cell recovery in the bone marrow was delayed after drug discontinuation

We demonstrated in previous chapters that ZDV plus SMX-TMP ablates B lineage
cell populations in the bone marrow. To determine whether discontinuation of the drugs
would result in recovery of bone marrow B cells, we examined total cellularity and total
B cells at 10, 14, and 24 days post-dosing. Total bone marrow cellularity had recovered
to control levels by day 10 post-dosing (Figure 4.1). The group of mice that received
only ZDV had a mean bone marrow cellularity that was significantly higher than that of
the control mice. Despite total bone marrow numbers being normal in the combination
group, we found that B lymphocytes were still significantly lower at this first timepoint
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Figure 4.1 Total and B cell population recovery after dosing discontinuation. Mice
were dosed with ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only for 21 days.
Bone marrow was harvested from the femurs of mice at various timepoints after dosing
was terminated. Cells were enumerated by counting, and the number of B lymphocytes
was determined by staining cells with fluorescently-labeled antibody specific for B220
assessed by flow cytometry. Data represent the mean ± SD of 4 mice per group and
are representative of multiple repetitions. *, P < 0.05 compared to vehicle only control.
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(Figure 4.1). To determine which B lineage cell types were affected to the highest
degree, we enumerated each of the B lineage subtypes present at each timepoint
(Figure 4.2). Cell types presented in Figure 4.2A through 4.2D correspond to their order
of maturity, with the number of cells recovered at each post-infection timepoint shown.
Pro-B cells (B220+/CD43+/HSAlow) were significantly depleted at day 10 post-exposure
(Figure 4.2B). Late pre-B cells (B220+/CD43-/IgM-) were affected to the largest degree,
with an 83% reduction in number compared to the control animals (Figure 4.2D). Day
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Figure 4.2 B lineage subtypes recovery after exposure termination. Mice were dosed
with ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only for 21 days. Bone marrow
was harvested from the femurs of mice at various timepoints after dosing was
terminated. Cells were fluorescently stained to delineate B lymphocyte precursors and
absolute number of each were determined by flow cytometry including, in their order of
maturation: pre-pro-B (B220+/CD43+/BP-1-/HSA-), pro-B (B220+/CD43+/HSAlow), early
pre-B (B220+/CD43+/BP-1+/HSA+), and late pre-B cell (B220+/CD43-/IgM-) subtypes in
panels A through D, respectively. Data represent the mean ± SD of 4 mice per group
and are representative of multiple repetitions. *, P < 0.05 compared to vehicle only
control.
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14 data demonstrated a partial recovery in these B lineage cell types, as statisticallysignificant differences were no longer observed, and by day 24 the B lymphocyte
populations in the bone marrow of combination treatment animals had made a full
recovery.

The cellular response to Pneumocystis was affected by the drug combination
primarily in the lung-draining lymph nodes

To assess the adaptive cellular response to Pneumocystis challenge during
reconstitution of bone marrow B lineage cells, cell phenotypes were analyzed in the
lung digest, BALF, and TBLN over time after infection. Lung lavage CD4+ and CD8+ T
lymphocyte and lung digest CD19+ B lymphocyte populations are shown in Figure 4.3.
No statistically-significant differences were observed at any timepoint in the T cell
populations in the BALF (Figure 4.3A-B) as a result of single drug or combination drug
exposure as compared to control animals. The numbers of alveolar infiltrating T cells
that displayed an activated phenotype (CD44hi/CD62Llo) likewise were not different
among the treatment groups compared to control mice (Figure 4.3D-E). Pulmonary
CD19+ B cell and activated B cell (CD80+ and/or CD86+) numbers were similar among
the groups at days 10 and 20 post-infection (Figure 4.3C and 4.3F). At day 6 postinfection however, total and activated B cells were significantly lower in the single drug
treatment groups versus the control group, but this was not the case for the combination
treatment animals. These differences were due to a wide range of total cell counts in
the lung digests at day 6 post-infection, and not because of differences in percentage of
these cell types.
TBLN CD4+, CD8+, and CD19+ cell populations were significantly reduced at days 10
and 20 post-infection in the mice that received both ZDV and SMX-TMP compared to
control mice (Figure 4.4A-C). Activated CD4+ T cells were fewer at day 10 postinfection in the combination group, but the difference at day 20 post-infection did not
reach statistical significance (Figure 4.4D). Activated CD19+ B cells did not increase in
response to the infectious stimulus on days 10 and 20 post-infection as they did in the
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Figure 4.3 Lung digest and BALF immune cell populations. Mice were dosed with
ZDV, SMX-TMP, ZDV plus SMX-TMP, or vehicle only for 21 days. After 4 days of rest
to allow the drugs to clear, mice were intratracheally inoculated with 1x107
Pneumocystis organisms isolated from a SCID colony of infected animals as detailed in
Materials and Methods. CD4+, CD8+ T cells, and their activated phenotype
(CD44hi/CD62lo), along with CD19+ B cells and their activated phenotype (CD80+ and/or
CD86+) were enumerated by flow cytometry in the BALF (T cells) and lung digest (B
d with highly active antiretroviral therapy</title><secondary-title>Aids</secondarytitle></titles><periodical><full-title>Aids</full-title></periodical><pages>F217-2 time in
panels D through F. Data represent the mean ± SD of 4 mice per timepoint per group
and are representative of 3 separate experiments. *, p < 0.05 as compared to the
vehicle only control group.
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Figure 4.4 T and B cells populations in TBLN. Mice were dosed with ZDV, SMX-TMP,
ZDV + SMX-TMP, or vehicle only for 21 days. After 4 days of rest to allow the drugs to
clear, mice were intratracheally inoculated with 1x107 Pneumocystis organisms isolated
from a SCID colony of infected animals as detailed in Materials and Methods. CD4+ T
cells, CD8+ T cells, CD19+ B cells, and their activated phenotypes (CD44hi/CD62lo T
cells and CD80+ and/or CD86+ B cells) were enumerated by flow cytometry in the TBLN
of mice at post-infection timepoints. CD4+, CD8+, and CD19+ cell counts were plotted
over time in panels A, B, and C, respectively. The activated phenotypes were plotted
over time post-infection in panels D, E, and F. Data represent the mean ± SD of 4 mice
per timepoint per group and are representative of 3 separate experiments. *, p < 0.05
as compared to the vehicle only control group.
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other groups (Figure 4.4F). Interestingly, the mice that received only ZDV had a
significantly elevated activated CD8+ cell number in the TBLN at day 6 post-infection
compared to control mice, and mice receiving only SMX-TMP had an increased number
of activated CD8+ cells at the day 20 post-infection timepoint (Figure 4.4E).

Pneumocystis clearance kinetics corresponded to decreased specific IgG titers in
drug combination-treated mice

Serum Pneumocystis antigen-specific IgG and IgM concentrations were measured
by semi-quantitative ELISA to evaluate the humoral response to pulmonary infectious
challenge after dosing with ZDV plus SMX-TMP. Figure 4.5A shows that a significantly
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Figure 4.5 Pneomocystis-specific serum IgG and IgM titers. Mice were dosed with
ZDV, SMX-TMP, ZDV + SMX-TMP, or vehicle only (controls) for 21 days. After 4 days
of rest to allow the drugs to clear, all mice were intratracheally inoculated with 1x107
Pneumocystis organisms isolated from a SCID colony of infected animals as detailed in
Materials and Methods. At days 6, 10, and 20 post-infection PC-specific IgG (panel A)
and IgM (panel B) endpoint dilution titers were determined by ELISA, with data from
days 10 and 20 post-infection shown. Data represent mean ± SD reciprocal endpoint
dilution for 4 mice per timepoint per group. *, p < 0.05 as compared to the control
group.
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lower Pneumocystis-specific IgG endpoint titer was seen in the mice that received
combination exposure compared to infected control mice at day 20. Additionally, there
was a trend toward a significant decrease at day 10 post-infection. Despite these
decreases in IgG, the IgM titers were not significantly affected by combination treatment
as compared to the single drug treatment and control animal groups (Figure 4.5B).
Decreased specific antibody levels corresponded to a trend toward a higher lung
Pneumocystis burden on day 20 post-infection (p=0.080). Although there was no

statistically significant differences in Pneumocystis nuclei present in the lung digest of
the combination treatment animals compared to controls at any timepoint (Figure 4.6),
the data at day 20 reflected a mean Pneumocystis burden that actually increased from
that of day 10 in the combination treated mice, whereas the Pneumocystis counts
continued to decline in each of the other groups. The group exposed to only SMX-TMP

Log10 Pneumocystis Lung Burden

had a lung burden significantly lower than the combination treatment group (Figure 4.6).

7.0

ZDV
SMX-TMP
Combination
Control

6.5

6.0

5.5

†

5.0

**

4.5
4

6

8

10

12

14

16

18

20

22

Days Post-Infection
Figure 4.6 Lung Pneumocystis burden. Mice were dosed with each drug for 14 days
as described in Materials and Methods and inoculated after 4 days of rest with 1x107
Pneumocystis organisms intratracheally. Lung burdens of PC were then determined
microscopically at days 6 through 20 post-infection. Data represent the mean ± SD
Pneumocystis organisms per lung of 4 mice per group per timepoint. †, p = 0.08 for the
combination treatment group compared to the control animals. **, p < 0.05 for the SMXTMP group compared to the combination treatment group.
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D. CONCLUSIONS

In this chapter we have shown that the toxicity caused by combination exposure to
ZDV and SMX-TMP impacts the ability of mice to fully respond to an infectious
challenge. We have demonstrated that mice treated with ZDV plus SMX-TMP prior to
Pneumocystis infection exhibits diminished B and T lymphocyte activation in the

draining lymph nodes of the lungs in response to this organism. The numbers of
infiltrating lymphocytes into the site of infection were not altered to a significant degree
as a result of combination drug exposure. However, clearance of pulmonary infection
with Pneumocystis in normal mice requires the use of a combination of cellular and
humoral components of adaptive immunity, therefore we additionally examined TBLN
lymphocyte populations, as well as antibody response (for a review, see Chapter 6).
TBLN populations of CD19+ B cells, as well as CD4+ and CD8+ T cells, were fewer in
number after the response to Pneumocystis as compared to control mice at days 10
and 20 post-infection. B cells are responsible for differentiating into plasma cells that
will secrete antibody against antigens associated with invading organisms. As a result
of decreased cell numbers in the draining lymph nodes, Pneumocystis-specific serum
IgG titers were significantly lower in mice that were exposed to the combination of ZDV
and SMX-TMP. Previous characterization of this combination toxicity (by our group and
others) revealed that peripheral T cell numbers in the spleen were unaffected (1). Here,
in the context of infection, total and activated CD4+ T cell frequencies were lower in the
TBLN of the combination treatment animals. This could be a direct effect of the drugs,
or a secondary effect stemming from the B cell depletion, which will be discussed
thoroughly in Chapter 6.
Although statistical significance was not reached, the clearance of Pneumocystis
appears to have stalled in the mice exposed to both ZDV and SMX-TMP. It would be
informative to extend this experiment to examine timepoints greater than 20 days postinfection. It is unknown why the SMX-TMP only group of mice had an enhanced
Pneumocystis clearance, as the 4 day rest period should have been ample time to clear

the drugs from these mice. There was a difference in Pneumocystis clearance between
the SMX-TMP only group, and the group that received both SMX-TMP and ZDV. Any
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enhanced clearance of the organism that occurred in the SMX-TMP only group was
ablated by the concurrent ZDV exposure.
Mice in the combination treatment group had a higher rate of mortality than mice
from the other treatment groups. Although the cause of death of these mice is
unknown, it is likely that they died as a result of the stress associated with pulmonary
inoculation, and not from Pneumocystis infection. Time to death was 1-3 days from
inoculation, and it would take much longer for an infection to develop from this slowgrowing organism. ZDV plus SMX-TMP exposure seems to render the mice vulnerable
to this stressor, perhaps due to an increased inflammatory response. More work is
needed to determine the reason for this increase mortality rate.
Overall bone marrow cellularity was restored by day 10 post-exposure, with all
subpopulations restored except for B lineage cells. Because pro-B and late pre-B cell
populations were not fully recovered until after day 14 post-dosing, the altered response
of B cells in the TBLN could be due to this residual bone marrow depletion in the mice
receiving ZDV plus SMX-TMP.
Together, these findings suggest that the toxicity associated with the use of ZDV and
SMX-TMP could adversely affect the immune response in HIV-infected patients as they
respond to vaccines as well as infectious agents. As the virus weakens the immune
function in these individuals, it is important to discern whether this drug-drug interaction
is propagating this impairment to a clinically-significant degree. Chapter 5 investigates
the clinical application of this work to address the impact of this toxicity in an HIVinfected patient population.

Copyright © David James Feola 2005
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CHAPTER 5: Clinical impact of combination drug exposure on host response

A. OVERVIEW

While HAART has an enormous impact on reducing morbidity and mortality in HIVinfected patients by decreasing viral load, these agents are not free from toxicity. The
effects of these agents on the immune function of HIV-infected individuals have been
underappreciated. Researchers have defined adverse effects of HAART using in vitro,
animal, and clinical investigations, which are reviewed extensively in Chapter 1. While
we have focused thus far on defining the toxicity with combination exposure to ZDV plus
SMX-TMP in mice, we now extend our study into a human population of HIV-positive
subjects to determine clinical relevance of this phenomenon. The yearly influenza
vaccine was used as a marker of host immunity to determine if response is altered in
patients receiving ZDV plus SMX-TMP.
Influenza types A and B are the two types of influenza viruses that cause epidemic
human disease (222). New influenza virus variants result from frequent antigenic
change (antigenic drift) due to point mutations occurring during viral replication. The
2004-2005 influenza virus vaccine (Fluzone®) contains inactivated viral hemagglutinin
antigenic determinants representative of three prototype strains: A/New
Caledonia/20/99, A/Wyoming/03/2003 (an A/Fujian/411/2002-like strain) and
B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain) (222). The vaccine contains the
hemagglutinins of these strains that are likely to circulate in the United States for the
winter months.
HIV infection has a detrimental effect on immune responses to infectious agents or
other forms of immune challenge, such as vaccination. This is due in part to the inability
of B lymphocytes to mount antigen-specific antibody responses, as outlined in detail in
Chapter 1 (52). Influenza vaccination of HIV-infected individuals has been extensively
studied, and the current recommendation from the CDC is to vaccinate all HIV infected
persons at the beginning of each influenza season (214). Investigators have shown,
however, that lower percentages of HIV-infected patients will adequately respond to this
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vaccine, demonstrated by the absence of protective influenza-specific antibody titers in
the serum in high percentages of patients (223-225). The success of this response has
been correlated directly with CD4+ count, and inversely with viral load (226, 227). It is
not known if the interaction between ZDV and SMX-TMP contributes to this inability to
produce an appropriate antigen-specific immune response, as clinical trials have not
reported which patients were receiving particular drug regimens for HAART and OI
prophylaxis. Since patients who have low CD4+ counts (below 200 cells/µl) are usually
on SMX-TMP, the interaction between SMX-TMP and ZDV could be a contributing
factor.
We therefore conducted a clinical trial to investigate the effects of this drug
combination on the ability of subjects to respond to an immune challenge. The animal
data presented in Chapter 4 revealed an altered antigen-specific antibody response in
mice exposed to ZDV plus SMX-TMP. The yearly influenza vaccine was utilized as a
marker of immune response in a group of healthy HIV-infected patients to determine
whether exposure to ZDV and SMX-TMP affected humoral immune function.
We hypothesized that humoral immunity would be altered as a result of combination
drug exposure. Our aims of the study were 1) to compare the antigen-specific antibody
response in patients vaccinated for influenza who were receiving ZDV and SMX-TMP
versus the appropriate control groups, 2) to compare peripheral blood lymphocyte
populations among the groups, and 3) to examine the relationship between CD4 count
and antigen-specific antibody response and how this relationship is altered with
combination drug exposure. We demonstrate that disease severity-matched patients
receiving both drugs have an altered antigen-specific response to influenza vaccination.

B. MATERIALS AND METHODS

Clinical Design

HIV-infected patients at the Bluegrass Care Clinic at the University of Kentucky
Chandler Medical Center were screened for inclusion, and informed consent was
obtained for those that met criteria and were willing to participate. HIV-positive patients
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between the ages of 18 and 65 years with CD4+ lymphocyte counts greater than 350
cells/μl, undetectable viral loads, and receiving a HAART regimen unchanged for
greater than 2 months were placed into one of four parallel treatment groups: 1) ZDV
only (300mg twice daily), 2) SMX-TMP only (one double-strength tablet daily), 3) ZDV
plus SMX-TMP, or 4) control group (receiving neither drug). Patients with high CD4+
counts and undetectable viral loads were included to minimize the effects of the disease
state on immune function.
Patients receiving ZDV as part of HAART were placed in either group 1, or were
given a 28-day course of SMX-TMP and placed in group 3. Patients not receiving ZDV
as part of HAART were placed either in group 4, or given a 28-day course of SMX/TMP
and placed in group 2 (Figure 5.1). Exclusion criteria consisted of the following: prior
vaccination for influenza or history suggestive of influenza infection during the 2004-05
season; current treatment with SMX/TMP or treatment within the past 2 months;
hypersensitivity to any component of the influenza vaccine, including eggs, egg
products, or thimerosal, or hypersensitivity to sulfonamides, TMP, or ZDV; current active
infection (other than HIV) or acute febrile illness within the past 30 days; known folate
deficiency or known glucose-6-phosphate dehydrogenase deficiency; pregnant patients
or nursing mothers; severe allergies or severe bronchial asthma; renal or hepatic failure;
and poor adherence to home medication regimens as deemed by patient, study
personnel, or treating physician.

Sample Collection

Baseline blood draws were obtained either on day 21 of the SMX/TMP course
(groups 2 and 3) or on the day of consent (groups 1 and 4), after which patients
received an intramuscular dose of the 2004 annual influenza vaccine (Fluzone®, Aventis
Pharmaceuticals,Bridgewater, New Jersey). Between 20 and 24 days after vaccination,
blood was again drawn to assess immune response to the vaccine. Blood was
collected by venopuncture into tubes coated with EDTA to keep the blood
anticoagulated. Cellular components were analyzed by flow cytometry immediately as
described below. Serum was separated from the cellular component and frozen at 800C for later analysis of influenza-specific IgG and IgM. The study design is depicted
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in Figure 5.1. Personnel analyzing patient samples were blinded to patient group
number. Note that patients were not randomly assigned to groups. The Institutional
Review Board approved this study and all of its procedures.

Flow cytometric analysis of peripheral lymphocytes

After serum separation, blood samples were incubated with fluorescently-labeled
monoclonal antibodies specific to human cell surface markers for T cells (CD4, CD8,
and CD25) and B cells (CD19, CD80, and CD86). Antibodies were purchased from
either Pharmingen (San Diego, CA) or eBioscience (San Diego, CA). Activated CD4+
and CD8+ T cells were defined as cells staining positive for CD25, the IL-2R alpha chain

Subjects on HAART with ZDV

Subjects on HAART without ZDV

SMX-TMP
Dosing (Day -21)

Group 1
ZDV only

SMX-TMP
Dosing (Day -21)

Group 3
ZDV + SMX-TMP

Group 2
SMX-TMP only

Group 4
Control

Pre-vaccine serum sample, influenza vaccination at Bluegrass Care Clinic, Day 0
(SMX-TMP dosing continues in Groups 2 and 3 through Day 7)

Post-vaccination blood sample, Day 20-24

Figure 5.1 Study design. Subjects meeting inclusion/exclusion criteria who were on
HAART +/- ZDV were placed into one of four groups as shown. Groups 2 and 3 were
generated by dosing subjects with a 28-day course of SMX-TMP. The influenza
vaccine was given on day 0, and a post-vaccination blood sample was obtained from
each patient 20-24 days later.
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that is up-regulated as the cells are activated. B cells were considered activated if
either CD80 or CD86 was up-regulated. Both CD80 and CD86 are receptors that are
up-regulated with B cell activation. A 100μl aliquot of whole blood for each sample was
placed into a tube containing antibodies for either the T or B cell panels, and incubated
for 15 minutes at room temperature. Erythrocytes were then lysed by the addition of
2ml of lysing solution containing ammonium chloride (0.15M), sodium bicarbonate
(10mM), and tetrasodium EDTA (1mM) for 10 minutes. Cells were then washed and
resuspended in PBS containing 1% paraformaledhyde for fixation. After gating on
lymphocyte populations defined by cell size and granularity, surface expression of each
marker was determined by flow cytometric multiparameter analysis using a
FACSCaliber Flow Cytometer (BD Biosciences, Mountain View, CA) and WinList
software package (Verity Software House, Topsham, ME). Greater than 50 thousand
events were routinely examined.

Antibody Titer Assay

Serum samples were thawed and sent to the medical reference laboratory ARUP
Laboratories (Salt Lake City, UT) for influenza A and B virus IgG and IgM antibody
quantification. Amount of antibody was compared to reference values using an ELISA
method. The reference range of 0.89 or less corresponds to a negative result (no
significant level of antibody present), 0.90 to 1.10 represents equivocal results,
indicating a questionable presence of virus-specific antibody, and values greater than or
equal to 1.11 indicate the presence of influenza antibodies at an immunoprotective titer.

Statistical Analysis

Data are expressed as mean ± standard deviation for cell population percentages
and antibody reference values. Differences between treatment groups and the control
group were determined by analysis of variance (ANOVA) followed by the StudentNewman-Keuls post-hoc testing where appropriate. Antibody responses (positive
versus negative/equivocal) between the combination drug treatment group and control
group were analyzed using Fisher’s Exact Test. Differences were considered
statistically significant when p was < 0.05. SigmaStat statistical software (SPSS, Inc.,
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Chicago, IL) was used for these analyses. Regression analyses of the relationships
between antibody response and CD4 count were compared for overall coincidence by
calculating the F-statistic to determine if a significantly better fit to the data is obtained
by fitting it with two separate lines compared to fitting all of the data with one regression
line. This F-statistic was then compared to the critical value F for p < 0.025 with the
appropriate degrees of freedom to determine statistical significance. This Type I error
rate was adjusted for multiple comparisons using the Bonferroni correction.

C. RESULTS

Subject demographics were homogeneous among study groups

Twenty-eight subjects were enrolled in the study, and 23 were included in the final
analysis. Two subjects developed a rash on SMX-TMP and were terminated from the
study, and 3 subjects did not return for post-vaccination blood sampling. The
demographics of the study population are outlined in Table 5.1. Each group had
between 5 and 7 individuals, with each group including one female. Mean subject age
and CD4+ lymphocyte counts were not significantly different among treatment groups.
The average mean corpuscular volume was significantly higher for the two groups that
received ZDV as compared to the control group. Macrocytosis is a known effect of
ZDV, and investigators have demonstrated that it is so reliable that it can be used to
monitor adherence to ZDV therapy (103, 106). All patients receiving ZDV were above
the normal erythrocyte mean corpuscular volume range of 88 to 98 μl.
Antiretroviral regimens varied from 3 to 6 agents, with a median number of 3 or 4 in
each group. All 23 patients were receiving an NRTI other than ZDV. Fifty-six percent
were receiving an NNRTI, and only 26% were receiving a PI. One patient in each
group, with the exception of the combination group, was receiving multiple PI. Subjects
recorded doses of ZDV and SMX-TMP in dosing diaries as a measure of adherence to
study protocol. One patient reported missing one dose of SMX-TMP, while one other
patient reported missing two doses of SMX-TMP. All other patients reported 100%
adherence to the study regimen of SMX-TMP, and to HAART.
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Table 5.1 Patient demographics.
Dosing Groups
Parameters

ANOVA

ZDV

SMX-TMP

Combination

Control

p-value

51.5 (46-61)

47.0 (32-59)

40.4 (26-47)

42.8 (32-54)

0.163

5/1

6/1

4/1

4/1

592.2 ± 333.5

692.8 ± 528.4

597.2 ± 254.5

850.8 ± 468.7

0.442

111.2 ± 6.6*

95.0 ± 11.2

109.4 ± 4.1*

92.8 ± 2.0

<0.001

NRTI, median (range)

3 (2-4)

2 (1-2)

2 (2-2)

3 (1-3)

NNRTI, median (range)

1 (0-1)

1 (0-1)

1 (0-1)

1 (0-1)

PI, median (range)

0 (0-2)

0 (0-3)

0 (0-1)

0 (0-2)

Total, median (range)

4 (4-6)

3 (3-4)

3 (3-3)

3 (3-4)

Age, mean years (range)
Gender, male/female
CD4, cells/μl (mean ± SD)
MCV, μm3 (mean ± SD)
HAART, number of agents

*, p-value deemed statistically significant if < 0.05. Representative of one-way
ANOVA with post-hoc multiple pair-wise comparisons to the control group by the
Student-Newman-Keuls Method.

Peripheral blood lymphocyte populations and activation

To investigate whether using ZDV concurrently with SMX-TMP has any effect on
peripheral lymphocyte populations, CD4+ T cell, CD8+ T cell, and CD19+ B cell
percentages were determined in blood samples before and after vaccination. Percent
CD4+ T cells, CD8+ T cells, and CD19+ B cells of the total peripheral blood cell
population (after red cell lysis) are reported in Figure 5.2 (panels A, C, and E,
respectively). No significant differences in cell populations in the three treatment groups
compared to the control group were demonstrated. Additionally, little difference is noted
between pre- and post-vaccination data.
The activated phenotypes of these populations were also determined and reported in
Figure 5.2. Percentages of activated CD4+ cells (CD4+CD25+) and CD8+ cells
(CD8+CD25+) were not significantly different before or after vaccination (panels B and
D, respectively). Of note, the percentage of activated CD8+ cells did show a trend
toward a decrease in the combination group compared to the control group of subjects
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Figure 5.2 Serum percentages of CD4+, CD8+, and CD19+ lymphocytes and their
activated phenotypes before and after vaccination with influenza. After being placed in
one of four treatment groups: ZDV, SMX-TMP, the combination of both, or neither
(control), as detailed in Materials and Methods, blood was drawn from subjects
immediately preceding influenza vaccination, and 20-25 days after vaccination.
Percentage of total cells in the peripheral blood (after red cell lysis) was determined for
CD4+ T cells, CD8+ T cells, and CD19+ B cells by flow cytometry (panels A, C, and E,
respectively). The percentage of these cells that were of the activated phenotype are
given in panels B, D, and F: CD4+CD25+ cells, CD8+CD25+ cells, and CD19+ cells
having up-regulated either CD80 or CD86. Statistical significance was not reached in
any of the above data when comparing treatment groups to control groups using
ANOVA for p < 0.05.
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(p=0.108). Percentage of activated B cells (CD19+ CD80+ and/or CD86+) also did not
show any differences between groups (panel F).

Pre-vaccination influenza-specific IgG was affected by combination drug
exposure

We examined antibody titers of the subjects before receiving the influenza vaccine to
determine if the drug treatments had any affect on pre-vaccination humoral immune
status. Positive IgG reference values (greater than 1.10) specific to either influenza A
or B would be indicative of past or current infection or immunization. Subjects in the
ZDV only and ZDV plus SMX-TMP groups had influenza A-specific serum IgG values
that were significantly lower than the control subjects (Figure 5.3A). This trend was also
present in the pre-vaccination influenza B-specific IgG values for each of these groups,
although the data did not reach statistical significance (Figure 5.3B). Mean reference
values corresponded with a lower percentage of subjects in the positive range for
influenza-specific IgG in the combination group (20%) versus the control group (100%).
This difference was significantly different (p=0.048, Fisher’s Exact Test) (Table 5.2).
Because IgM is an indicator of recent or current infection or immunization, almost all
patients tested influenza-IgM negative at pre-vaccination (Figure 5.3A and B).
However, patient C04 tested positive to influenza A, and patient D03 tested positive to
both influenza A and B. This could indicate recent exposure in each of these
individuals, although both reported no recent history of flu-like illness. The mean
influenza-specific IgM values were not different among the groups at the pre-vaccination
timepoint (Figure 5.3C and D).

Drug exposure affected both post-vaccination influenza-specific IgG and IgM

To determine the humoral response to the vaccine among the patient groups, we
measured serum titers of IgG and IgM that were specific to influenza antigens within a
window of 20-25 days post-vaccination. Influenza-B specific IgG titers post-vaccination
were significantly lower in both the SMX-TMP only and combination treatment groups
compared to the control group (Figure 5.3B). This trend was mirrored in the
combination treatment group in response to influenza A, although the effect did not
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Figure 5.3 Serum antibody titers. After being placed in one of four treatment groups:
ZDV, SMX-TMP, the combination of both, or neither (control), as detailed in Materials
and Methods, blood was drawn from subjects immediately preceding influenza
vaccination, and 20-25 days after vaccination. Serum influenza A and B-specific IgG
and IgM titers were obtained by ELISA. *, statistically significant difference detected
when compared to control group using ANOVA for p < 0.05.

reach statistical significance (Figure 5.3A). Only 60% of patients in the combination
treatment group had a positive protective influenza A serum IgG response, compared to
100% in each of the other groups (Table 5.2). With regards to influenza B, serum IgG
values only reached the protective range in 1 patient (20%) in the combination group
versus 100% of the subjects in the control group, this difference being statistically
significant (p=0.048, Fisher’s Exact Test).
Interestingly, post-vaccination serum IgM titers reached the positive range in 100%
of patients in the combination group for both influenza A and B, versus 40% and 20% in
the control group for influenza A and B, respectively (Table 5.2). This corresponded
with a trend of an increase in mean IgM values for both influenza A and B in the
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combination group versus the control group (Figure 5.3C and D). Due to a high degree
of variability in IgM titers among the subjects, there differences did not reach statistical
significance (Figure 5.3C and D).
Table 5.2 Subject response to influenza vaccine.
Influenza A IgG
Pre-vaccination

Influenza B IgG

Influenza A IgM

Influenza B IgM

Negative + Equivocal / Positive (Percent Positive)

ZDV

2/4 (66)

5/1 (16)

6/0 (0)

6/0 (0)

SMX-TMP

1/6 (86)

3/4 (66)

7/0 (0)

7/0 (0)

Combination

4/1 (20)*

4/1 (20)

4/1 (20)

5/0 (0)

Control

0/5 (100)

1/4 (80)

4/1 (20)

4/1 (20)

ZDV

0/6 (100)

2/4 (66)

3/3 (50)

5/1 (16)

SMX-TMP

0/7 (100)

4/3 (43)

3/4 (57)

5/2 (28)

Combination

2/3 (60)

4/1 (20)*

0/5 (100)

0/5 (100)*

Control

0/5 (100)

0/5 (100)

3/2 (40)

4/1 (20)

Post-vaccination

Influenza-specific antibody reference values were measured in the serum on the day
of vaccination (pre) and 20-25 days after vaccination (post). The number of negative
(less than 0.89) plus equivocal (0.90-1.10) results are reported, along with the
number of subjects that tested positive (greater than 1.11) and the percentage that
tested positive. *, p-value statistically significant if < 0.05 when treatment groups
were compared to the control group using Fisher’s Exact Test.

Relationship between IgG response and CD4 count was affected by SMX-TMP
exposure

Because antibody production, and specifically class switching, is reliant upon T and
B cell interactions, and because T cells exhibit a positive correlation to antigen-specific
antibody titers in patients infected with HIV, we compared the strength of this correlation
among the different treatment groups before and after vaccination. Influenza A and Bspecific serum IgG titers were graphed versus CD4+ cell numbers for the prevaccination (Figure 5.4) and post-vaccination (Figure 5.5) blood samples. Figure 5.4
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depicts influenza A- (panels A and B) and influenza B- (panels C and D) specific prevaccination IgG titers as a function of CD4+ cell count. The combination treatment
group was compared to the control group (panels A and C) and the 2 groups that
received SMX-TMP were compared to the 2 groups that did not receive SMX-TMP
(panels B and D).
Statistical analysis comparing regression lines for these figures are summarized in
Table 5.3. Regression analyses of the relationships between antibody response and
CD4 count were compared for overall coincidence by calculating the F-statistic to
determine if a significantly better fit to the data is obtained by fitting it with two separate
Table 5.3 Regression data comparing IgG to CD4.
Pre-vaccination
Influenza A

n

r

F

Crit F

Test

Control

Pooled

Test

Control

Pooled

Combo vs Control

5

5

10

0.636

0.209

0.266

26.13

7.26

+/- SMX-TMP

11

11

22

0.080

0.162

0.140

1.69

4.56

Combo vs Control

5

5

10

0.460

0.248

0.018

3.22

7.26

+/- SMX-TMP

11

11

22

0.144

0.219

0.187

0.05

4.56

Combo vs Control

5

5

10

0.840

0.804

0.331

8.72

7.26

+/- SMX-TMP

11

11

22

0.488

0.427

0.044

3.60

4.56

Combo vs Control

5

5

10

0.237

0.460

0.422

11.70

7.26

+/- SMX-TMP

11

11

22

0.056

0.210

0.110

5.95

4.56

Influenza B

Post-vaccination
Influenza A

Influenza B

Regression analyses of the relationships between antibody response and CD4 count
were compared for overall coincidence by calculating the F-statistic to determine if a
significantly better fit to the data is obtained by fitting it with two separate lines
compared to fitting all of the data with one regression line (pooled). This F-statistic
was then compared to the critical value F for p<0.025 with the 2,n-4 degrees of
freedom. F values reaching statistical significance are shown in bold.
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lines compared to fitting all of the data with one regression line (pooled). Sample sizes
(n) and r values are given for each analysis.
The relationship between influenza A-specific IgG response and CD4+ cell count was
significantly different for the subjects receiving ZDV plus SMX-TMP compared to
subjects in the control group (Figure 5.4A). This difference corresponded with lower
influenza A-specific IgG titers at the corresponding
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Figure 5.4 Pre-vaccination IgG titer correlation with CD4 cell count. After being placed
in one of four treatment groups: ZDV, SMX-TMP, the combination of both, or neither
(control), as detailed in Materials and Methods, blood was drawn from subjects
immediately preceding influenza vaccination, and serum influenza A and B-specific IgG
titers were obtained by ELISA. These titers were plotted versus the corresponding
subject’s CD4 T cell count for influenza A (panels A and B) and influenza B (panels C
and D) comparing the combination treatment group versus the control group (panels A
and C) and comparing the groups that received SMX-TMP versus those that did not
receive SMX-TMP (panels B and D). **, statistically significant difference when
comparing the F-statistic to the critical value of F for p<0.05 when testing regression
lines for coincidence.
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CD4+ T cell counts. A difference in regression lines was not observed when
comparing the combination treatment group versus the control group for influenza B
(panel B), or when comparing subjects receiving SMX-TMP versus subjects not
receiving SMX-TMP for influenza A or B (panels B and D, respectively).
Figure 5.5 depicts influenza A- (panels A and B) and B- (panels C and D) specific
post-vaccination IgG responses as a function of CD4+ cell count, comparing the
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Figure 5.5 Post-vaccination IgG correlation with CD4 cell count. After being placed in
one of four treatment groups: ZDV, SMX-TMP, the combination of both, or neither
(control), as detailed in Materials and Methods, subjects were vaccinated with the
influenza vaccine, and after 20-25 days, blood was drawn and serum influenza A and Bspecific IgG titers were obtained by ELISA. These titers were plotted versus the
corresponding subject’s CD4 T cell count for influenza A (panels A and B) and influenza
B (panels C and D) comparing the combination treatment group versus the control
group (panels A and C) and comparing the groups that received SMX-TMP versus
those that did not receive SMX-TMP (panels B and D). **, statistically significant
difference when comparing the F-statistic to the critical value of F for p<0.05 when
testing regression lines for coincidence.
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combination treatment group versus the control group (panels A and C) and comparing
the groups that received SMX-TMP versus group that did not receive SMX-TMP (panels
B and D). Regression lines did not coincide with one another in panels A, C, or D. We
conclude that the relationship between serum IgG titer and CD4+ count was statistically
different for subjects exposed to ZDV plus SMX-TMP versus control subjects for both
influenza A and B (panels A and C, respectively). Likewise, the relationship between
serum IgG and CD4+ count was different among subjects in who received SMX-TMP
and subjects who did not receive SMX-TMP for influenza B (panel D). A significant
difference was not observed in panel B. These differences are shown in Table 5.3, with
F values greater than the critical F values at p < 0.025.

D. CONCLUSIONS

In this chapter we have demonstrated the clinical impact of concurrent treatment with
ZDV and SMX-TMP on immune response when using the influenza vaccine to
challenge subjects infected with HIV. Peripheral blood lymphocyte percentages were
not affected, but despite a lack of differences in demographics between groups, the
subjects in the combination treatment group had a lower mean influenza B-specific IgG
titer in the serum compared to the control group in response to vaccination.
Interestingly, exposure to the combination of agents for 21 days lowered influenzaspecific IgG titers at the pre-vaccination sampling as well. Influenza-specific IgM serum
titers were actually higher in the group of subjects exposed to ZDV plus SMX-TMP as
compared to disease-severity matched control subjects 20-25 days post-vaccination.
These differences could be indicative of a suppression of the humoral response, or they
could be representative of an alteration in timing of this response.
The majority of the subjects tested positive for influenza-specific IgG, which likely
corresponds to the fact that they each received the influenza vaccine during the
previous year. Although subjects reported having no flu-like illness during this year’s
influenza season, recent exposure to the virus cannot be ruled out as a cause for
protective IgG levels. Because the assay used cannot distinguish between antigenic
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differences from this year’s vaccination and those of the previous years, this is a
potential source of error for our data. Comparisons of pre-vaccination immune status
should therefore be considered cautiously. It would have been helpful to also obtain a
blood sample to analyze IgG titers prior to SMX-TMP dosing. Because this was not
performed, a true baseline for influenza-specific IgG was not established.
This difference in antibody profile among the groups could indicate an impaired
ability of the combination treatment subjects to effectively isotype switch antibody
production. B cells constitutively express the IgM isotype in response to an infectious
challenge. In order for the host to produce other isotypes, the process of isotype
switching must occur, which will then allow cells to produce, among other isotypes,
antigen-specific IgG. This process is dependent on B cells interacting with T cells in
secondary lymphoid tissues, and will be discussed in detail in Chapter 6. Subjects
receiving SMX-TMP had influenza-specific IgG responses that did not positively
correlate with CD4+ counts to a similar degree as subjects that did not receive SMXTMP. These results could indicate that the adverse effects of these drugs could be
influencing humoral immune responses to a clinically significant degree.
One limitation to these data concerns the low level of power in statistical analyses
comparing CD4 correlation with IgG responses due to the low numbers of subjects in
each treatment group. Tests between groups routinely had power levels below the
desired power level of 0.80. Although poorly-powered comparisons increase the
likelihood of not detecting differences that exist between samples, we were able to
detect statistical differences among our treatment groups in several instances. Other
differences may exist that were not identified, therefore negative results must be
interpreted cautiously. The percentages of subjects with positive influenza-specific
antibody titers in the treatment groups were compared to the control group using
Fisher’s Exact Test, but corrections for multiple comparisons were not utilized. These
statistical differences should therefore be interpreted cautiously. A larger study with a
higher number of subjects in each group, along with serial timepoints post-vaccination
to more accurately describe antibody responses, is warranted.
Copyright © David James Feola 2005
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CHAPTER 6: Discussion

A. RESULTS SUMMARY

Our investigations have characterized the toxicity caused by concurrent ZDV and
SMX-TMP exposure. We first began in mice, to define the nature of the toxicity in
immune cell populations in primary and secondary lymphoid tissues, as well as a
common site of infection, the lungs. We also characterized the effects of this drug
combination on the host’s response to an immune challenge, using pulmonary
Pneumocystis as the model of infection. Our investigations then turned in opposing

directions. In a series of in vitro experiments, we asked basic questions relating to the
mechanism of the toxicity to B lymphocytes in the bone marrow. Finally, we explored
the clinical relevance of this drug-drug interaction to discover an altered humoral
immune response to influenza vaccination in HIV-positive patients exposed to both ZDV
and SMX-TMP. Hypotheses generated from this work which will guide the future
directions of this project are discussed below.
There are three potential reasons for the synergistic toxicity. First, sequential sites of
toxicity along the development pathway could cause synergy to occur, thereby
amplifying the overall depletion. Alternatively, combination exposure could cause
additive or synergistic DNA damage, increasing the percentage of cells that suffer
apoptosis. And finally, one drug could alter the disposition of the other agent or its
metabolites, thereby resulting in increased cytotoxicity. These mechanisms are not
mutually-exclusive of one another.

B. MECHANISM

Our mechanistic investigation of this drug-drug interaction is in its infancy. There are
two categorical elements to the potential cause of the increase in apoptosis observed.
First, the presence of the combination of agents could be pharmacodynamically
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responsible for the toxicity. It is possible that each drug’s unique effect, whether on a
molecular or cellular level, when combined cause this synergistic toxicity. Second, the
disposition of one agent or its metabolites could be affected by the presence of the
other, thereby causing a localized pharmacokinetic interaction in the bone marrow. We
have conducted experiments to partially address each element, which are discussed in
detail in the points that follow.

Pharmacodynamics
Sequential sites of development. By analyzing specific subpopulations of the B-

lineage, we demonstrated that subtypes in the more rapidly-dividing stages of
development are the most sensitive to apoptosis induced by ZDV plus SMX-TMP. B
lymphocytes serve as an excellent line in which to study this phenomenon because of
the extensive work performed by several groups to phenotypically characterize the
discrete stages of B-lineage cells and the processes occurring at each of these stages.
This allowed us to investigate the characteristics of toxicity to individual cell types as
they mature, to consider whether cytotoxicity in sequential stages could cause the
synergistic effect of B cell depletion.
We conclude here that the rapidly-dividing early pre-B cell fraction is a focal point of
toxicity in mice exposed to the combination of ZDV and SMX-TMP as evidenced by the
early block in early pre-B cell proliferation at day 7 of dosing followed by a significant
reduction in late pre-B cells by dosing day 15. In addition, by dosing day 21, the more
immature cells of the pre-pro-B and pro-B phenotypes were depleted significantly in the
single drug treatment groups as well as in the combination treatment group. Therefore,
fewer cells reached the proliferative pre-B stages in each of these three groups.
However, only mice exposed to the combination of agents had overall B lymphocyte
populations depleted in the bone marrow, demonstrating that only with pre-B cell burstinhibition is the overall number of B cells significantly affected. Two separate sites of
toxicity is likely a contributing factor to the synergistic effect observed. The mechanism
of toxicity at each point could be the same, because pro-B cells are also proliferating,
albeit at a slower rate.

94

An alternative mechanism of toxicity could be a direct affect on the stromal cells of
the bone marrow. This could lead to altered B cell development due to the vital support
that stromal cells provide. Stromal cells do not rapidly divide, so if indeed the
mechanism of cell death is tied to proliferation, it is unlikely that the stromal cells are
involved. However, stromal cells do provide necessary signals to B lineage cells as
they develop, the absence of which could induce apoptotic cell death. The impact of
combination drug therapy on stromal cells is unknown.
DNA damage. From the analysis of our findings, we hypothesize that the apoptosis

in B-lineage cells that results from exposure to ZDV plus SMX-TMP is due to
overwhelming DNA damage. We reach this premise for 3 reasons. First, known
mechanisms of bone marrow toxicity for each agent individually involve the inhibition of
DNA replication. The inhibition of thymidylate kinase by ZDV-monophosphate leading
to the depletion of thymidine stores, combined with the inhibition of nucleic acid
synthesis by SMX and TMP, could synergistically target highly proliferating early pre-B
cells. Furthermore, oxidative stress associated with SMX-NO and SMX-HA could
contribute to DNA damage as well.
Second, we have shown that the effect is specific to the proliferation phases of the
cell cycle. At dosing day 7 we found a buildup in cell number in these phases in the
early pre-B subset and a slight decrease in the number of late pre-B cells, suggesting
that they are unable to progress to mitosis. The fact that the percentage of cells in
G0/G1 is reduced by the drug combination, in addition to the depletion observed in the
late pre-B cell subset (and with extended dosing, in the early pre-B subset also), leads
us to believe cells are arrested in the proliferative phases. Cell cycle arrest that causes
a buildup of cells in the S and G2 phases results from a failure to proceed through the
“checkpoint” to the mitotic stage, prohibiting their division. This step is regulated by the
enzyme M phase kinase (228, 229). Cells are prohibited to begin mitosis at this
checkpoint if DNA is highly damaged during replication, or if the cell does not have the
ability to adequately repair it (230, 231).
The third reason to consider this hypothesis is because the cell death caused by
ZDV plus SMX-TMP appears to be caspase-independent. While most forms of
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apoptosis induction proceed through either the intrinsic or extrinsic pathways, both of
which rely on signaling and effector caspases to induce programmed cell death, there
exists a mechanism through which apoptosis can be induced without the requirement of
caspases. This caspase-independent apoptosis is triggered by DNA damage. Our
results in Chapter 3 support this notion, in that the cytotoxicity was not hindered by pancaspase inhibition.
Caspase-independent apoptosis. Mitochondria play an important role in

programmed cell death through the release of cytochrome c and apoptosis-inducing
factor (AIF), which activate caspase-dependent and caspase-independent apoptosis
mechanisms, respectively. Poly(ADP-ribose) polymerase 1 (PARP-1) is an important
activator of AIF release from the mitochondria. DNA damage causes the up-regulation
of PARP-1, which triggers the release of AIF (232). Although caspases may be
involved in facilitating cell death mediated by the release of AIF from the mitochondria,
they are not required, as broad-spectrum caspase inhibitors do not prevent PARP-1mediated cell death (67). In addition to PARP-1 up-regulation, AIF release from
mitochondria can be stimulated by the intrinsic apoptosis pathway or by changes in
mitochondrial membrane potential (233). AIF entering the nucleus causes classic
apoptotic features in the cell, including chromatin condensation, phosphatidylserine
exposure on the cell surface, and mitochondrial membrane depolarization, all in the
absence of caspase activation (67, 234, 235).
PARP-1 activation mediates cell death in ischemia-reperfusion injury, inflammatory
injury, and reactive oxygen species-induced injury (236-239). The effects of ZDV and
SMX-TMP on DNA replication could be inducing an increase in PARP-1 cleavage
leading to induction of apoptosis in B cells.
One caveat that does not support this premise is that ZDV has been demonstrated to
cause apoptosis that is caspase-dependent (120, 240). The mitochondrial damage
associated with ZDV’s inhibition of DNA polymerase gamma causes cytochrome c
release that triggers the intrinsic apoptosis cascade (120, 240). Further work is needed
to investigate each mechanism’s contribution to apoptosis when both ZDV and SMXTMP are present. An ideal next step would be to determine mitochondrial release of
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cytochrome c and AIF, as well as mitochondrial membrane potential and permeability, in
the setting of combination drug exposure compared to appropriate controls.
Defining this more clearly would not only supply insight into the mechanism of this
combined toxicity, but this information could also provide therapeutic potential to this
drug combination with respects to cancer treatment. Recently, several papers have
given promise to ZDV and its ability to cause apoptosis to occur in several types of
malignancy, including lymphoma, multiple myeloma, and parathyroid cancer cells (241244). Combining this therapeutic effect with SMX-TMP has not been investigated. This
could be tested by exposing various B lymphoma cell lines to the combination of ZDV
and SMX-TMP in vitro, and determining if apoptosis can be induced.

Pharmacokinetics
Alteration of drug disposition. The final possible mechanism that has been

addressed is that of drug disposition alteration. Because steady-state serum SMX
concentrations were elevated in mice concurrently receiving ZDV, we became
interested in the potential causes of this alteration, and the impact that it has on
cytotoxicity in the bone marrow. Pharmacokinetic investigations have not previously
demonstrated interactions involving combination use of SMX-TMP and ZDV. Although
SMX-TMP caused a significant decrease in renal clearance of ZDV and its glucuronide
metabolite in a study involving 9 patients infected with HIV, the overall net clearance of
ZDV was not affected (158). In another investigation, concomitant SMX-TMP therapy
did not alter the AUC of ZDV in 16 HIV-positive patients (245). To our knowledge, our
data is the first to suggest that ZDV may affect the disposition of SMX.
Mrp4 expression induced by ZDV could be affecting GSH pools in lymphocytes,
thereby increasing the intracellular concentrations of the oxidative metabolites of SMX
(see Chapter 3). This would then induce increased amounts of oxidative stress which
could lead to DNA damage and caspase-independent apoptosis. This could lead to the
alteration in serum concentrations of SMX, as systemic clearance would be delayed by
the sequestering of SMX in the intracellular compartment. The fact that it takes 72
hours of exposure for ZDV to contribute to the toxicity in our in vitro system could be
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due to the time required to up-regulate Mrp4, although the timing of this phenomenon
has not been defined (207).
Unfortunately, our study of this premise is in its infancy. Confusing results were
reached during our experiments with Mrp1-/- mice, from which no credible conclusions
can be drawn at this time. Future studies will involve intracellular concentration
determinations of SMX, SMX-NO, and SMX-HA, as well as Mrp4 expression
determination on B cells exposed to ZDV. GSH concentrations, as well as GSH-SMX
metabolite levels, will also be investigated. It would also be interesting to determine if
concurrent dosing of antioxidants would have an inhibitory effect on this drug-drug
interaction.

C. EXPERIMENTAL CONSIDERATIONS

Concentration-dependent cytotoxicity in vitro

The in vitro system utilized in this work is not representative of the B-lineage cellular
makeup of the bone marrow in several ways. In vivo, B-lineage cells are under the
influence of many cytokines and cell-cell interactions as they mature. With the
exception of IL-7 (which we supplement), normal stromal cell interactions are absent
(see Chapter 1 for a review). The IL-7 therefore biases our population toward the early
pre-B and late pre-B cell subtypes that are responsive to its stimulation to proliferate.
This forces us to acknowledge that the results that we observe in vitro may not be
entirely representative of in vivo phenomena. However, as demonstrated in Chapter 2,
these pre-B cell stages are the primary focus of the combined toxicity observed in vivo,
so our culture system does have merit.
It is logical to think that this would make cells in our culture system exquisitely
sensitive to apoptosis induction by our drug combination. Although serum trough
concentrations of the parent SMX reach over 100μg/ml in our in vivo experiments, the
more relevant information is the intracellular SMX metabolite concentration changes
inside B cells. When ZDV exposure was lengthened to 72 hours, B lymphocytes in our
culture system underwent rapid apoptosis induction with the addition of SMX-HA.
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Intracellular concentrations of SMX-NO and SMX-HA are topics of ongoing
investigation.
Comparing Figures 4.2B and 4.4D, we find the percentage of apoptotic B cells to be
much higher at low SMX-HA concentrations (and well past its peak at higher SMX-HA
concentrations) after exposure to ZDV for 72 hours (Figure 4.4D). Because of this,
apoptosis was best studied in the first few hours of SMX-HA exposure, as reflected in
the caspase inhibitor experiments.

Dosage relevance

The doses used in the animal experiments corresponded with doses used in studies
by other investigators (1, 123, 246). The doses administered to the mice in these
experiments were approximately 8-10 times the doses given to humans for
Pneumocystis pneumonia prophylaxis and HAART; however, the doses were more

comparable to humans doses based on body surface area (80, 214). Interspecies
scaling in drug dosing has received much attention, as it is a continual problem when
using animals to model and investigate human conditions (247, 248). Mice have been
shown to require much higher doses of cytotoxic drugs than humans to produce similar
levels of cell death (249, 250). The therapeutic range for SMX in humans is 50-200
μg/ml in the serum according to the manufacturer’s information for SMX (Hoffman-La

Roche, Basel, Switzerland). The serum concentrations of SMX were measured in our
mice to be between 45 and 95 μg/ml, which are comparable to those found in humans;
although, the mean serum concentrations over the entire dosing interval would be much
higher. The extent to which the concentrations of SMX-HA, SMX-NO, and ZDV in
mouse bone marrow correlate with humans treated with these agents is unknown.
Furthermore, the presence of HIV infection would likely worsen the toxicity of this drug
combination, due to the intracellular GSH reductions in HIV patients as outlined
previously. This issue makes it difficult to predict the clinical significance of such
results, making human investigations extremely important.
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D. HOST RESPONSE

Lymphocyte populations in secondary lymphoid tissues

Of note, cells in secondary lymphoid tissues were not studied for apoptotic
characteristics associated with combination drug exposure. Apoptotic frequency could
be increased here as well, especially in an infectious response, as cells undergo rapid
divisions as clonal expansions of T and B cells occur. Along with previous reports by
others, we show in Chapter 2 that ZDV plus SMX-TMP do not affect peripheral T cell
numbers in the spleens of uninfected mice (1). In the context of infection, however, total
and activated CD4+ T cell frequencies were lower in the LN draining the site of infection
(Chapter 4).
This could be either a direct effect on expanding T cell populations, or a secondary
effect stemming from the B cell depletion. Investigators have shown that T cell
responses are dependent on interactions with B cells in secondary lymphoid organs in
response to many infectious stimuli, including Salmonella, Bordetella pertussis vaccine,
and Pneumocystis (219, 251, 252). By evaluating antigen-specific cytokine secretion by
CD4+ cells in normal and B cell-deficient mice, Linton et. al. determined that B cells play
a critical role in regulating clonal expansion of CD4+ cells (252). Ugrivovic et. al.
suggest that T cell responses to Salmonella infection are dependent on B cell antigen
presentation (251). Additionally, our group demonstrated that T cell expansion and
activation are reduced in TBLN and the lungs of B cell-deficient and CD40 knockout
mice in response to Pneumocystis infection (219).

Peripheral blood B lymphocytes

No clinical literature exists showing an effect of drug combination treatment on the
number of B lymphocytes in the peripheral blood. Consistent with this, we were unable
to detect changes in the percentage of peripheral blood B cells in mice treated with the
drug combination, or in patients receiving ZDV and SMX-TMP in our clinical study.
However, this does not preclude the possibility that the peripheral B cell compartment is
altered in patients in the lymph nodes and spleen.
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Interesting work has shown that IL-7 knockout mice, which have B lymphocyte
production only during fetal and perinatal life, still maintain a stable pool of B cells in
peripheral organs including the spleen (253). However, these B cells consist only of the
B1 and marginal zone phenotypes, accompanied by a 50-fold increase in the frequency
of IgG secreting cells and increased serum antibody titers (253). Folicular B cells, the
opposite phenotype, responsible for responding to BCR stimulation to produce high
affinity antibodies, are absent in these knockout mice (253). This is extremely similar to
patients with advance HIV disease that have altered antibody profiles as discussed
earlier. This applies clinically, in that bone marrow depletions of developing B cells may
not be reflected in the peripheral blood of patients. A future goal of this project is to
determine the effect of ZDV and SMX-TMP on the various peripheral B cell subtypes.

Immune response to Pneumocystis

It is not surprising that the abnormalities in the B cell compartment caused by ZDV
plus SMX-TMP do not prohibit the clearance of Pneumocystis. Pulmonary infection with
Pneumocystis is cleared in normal mice, requiring the use of a combination of cellular

and humoral components of adaptive immunity. It has been shown that mice cannot
mount an effective host response to Pneumocystis without the presence of CD4+ T cells
(215, 216, 254). Alveolar macrophages are the likely effector cells responsible for killing
Pneumocystis since depletion of alveolar macrophages in rats resulted in the inability to

clear infection (255). Additionally, it has been demonstrated that mice deficient in B
cells are also susceptible to Pneumocystis infection and are rendered unable to resolve
a primary infection (217-219, 256). In the present study, the numbers of infiltrating
lymphocytes into the site of infection were not altered to a significant degree.
Several investigators have demonstrated that IgG produced by B cells facilitates the
clearance of Pneumocystis in murine models of infection (257-261). Work from our
laboratory recently demonstrated, however, that Pneumocystis-specific IgG plays an
important, but not critical, role in the defense against Pneumocystis (219). This
corresponds with the data presented in Chapter 4 in that the mice that received both
ZDV and SMX-TMP were able to control the Pneumocystis burden in the lungs despite
reduced serum IgG concentrations. Our data indicate that clearance of Pneumocystis
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was able to proceed to a certain point and then stalled. This is consistent with other
data from our laboratory in which we found a delay in the clearance of Pneumocystis in
mice unable to produce Pneumocystis-specific isotype class-switched antibody (219).
The fact that IgM (which is constitutively expressed) titers were not significantly reduced
indicates that B cells from mice receiving both ZDV and SMX-TMP may have a
decreased ability to isotype switch to produce IgG.

Isotype switching

All naïve B lymphocytes express IgM and IgD constitutively on their cell surfaces.
After interacting with T cells in T cell zones of the LN, B cells begin secreting IgM as
well, especially in the initial stages of a primary immune response. Some of these B
cells migrate to a primary lymphoid follicle, where they form a germinal center (262).
Classes of antibody other than IgM are only produced by B cells that undergo isotype
switching, which occurs here in the germinal center. Most antibody in the plasma is
class-switched antibody of the IgG isotype. This switch occurs as a result of B cells
interacting with helper CD4+ T cells (263, 264). B cells express a particular antigen on
their surface in the context of MHC II. This cross-links with the TCR of a T cell that has
been primed with the same antigen. CD40 on the B cell surface then ligates to CD40L
on the surface of the T cell, providing a secondary signal to the B cells to stimulate class
switching and antibody production (263, 264). Additionally, cytokine excretion from T
cells (IL-4, IL-5, and TGF-β) also stimulates B cells, to govern which isotypes are
produced by that particular cell (265). Combination exposure to ZDV and SMX-TMP
could be influencing this interaction in some manner. Although peripheral T cell
numbers have not been shown to be affected, Freund et. al. did demonstrate an
alteration in T cell function as a result of ZDV plus SMX-TMP exposure (1).
In addition to isotype switching, it is in the germinal center that antibody production
also undergoes somatic hypermutation and affinity maturation, in order to produce
antibody that displays a high affinity to a specific antigen (266, 267). This occurs as
cells are rapidly dividing. The toxicity of ZDV plus SMX-TMP could have an impact on
these germinal center cells as they divide. This could account for the lower IgG titers
that are observed both in the mice challenged with Pneumocystis, and in the HIV-
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infected subjects that were vaccinated against influenza. This antibody with high affinity
is the very type that is absent in patients with HIV. This drug affect could be
contributing to this condition in these patients. Important future work will be to
investigate the different B cell phenotypes in the context of infection, to determine
whether ZDV plus SMX-TMP exposure results in selective depletion of follicular B cells.
Our data also suggests that IgG antibody titers from previous vaccination or infection
are decreased by combination drug exposure. Subjects in the combination drug group
had significantly lower pre-vaccination IgG levels. Many factors could have influenced
this data since baseline titers before drug treatment were not measured. These include
varied exposure to influenza and variable CD4 counts when previously vaccinated.
While this should be interpreted conservatively, this data could signify a depletion of
plasma cells that have migrated from the germinal centers to the bone marrow, which
take up residence there and are very long-lived (268). These cells produce high-affinity,
antigen-specific antibody for long periods. Bone marrow toxicity to B lymphocytes could
include these plasma cells, although the fact that they are not rapidly dividing could
protect them. This hypothesis will be tested in the future by analyzing this subtype of
plasma cells that reside in the bone marrow. Additionally, affects on B cell memory as a
result of drug exposure would also be interesting to investigate.

Response to vaccination

Immunoprotection is achieved with inactivated influenza vaccination in normal
persons at a success rate of 70 to 90% (269). This declines for HIV patients as CD4
counts decrease (223-226, 270). Kroon et. al. measured the proportion of HIV-positive
patients with CD4 counts greater than 300 cells/μl that have protective antibody titers
from influenza vaccination in a 3-year study (270). At 30 days post-vaccination, 50 to
100% of subjects had protective antibody titers for influenza A, compared to healthy
controls with 81-100% protective titer rates (270). Protective titer rates for influenza B
were lower; between 64 and 75% versus 86 to 100% for healthy controls (270). This
compares with our overall response rates for serum IgG in our subjects of 91% for
influenza A and 56% for influenza B (our subjects had CD4+ counts greater than 350
cells/μl). The difference in our study compared to the study conducted by Kroon et. al.
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is that subjects cohorted to receive SMX-TMP in our investigation caused this group to
have lower response rates of 83% and 33% for influenza A and B, respectively. It
appears that SMX-TMP exposure causes protective titers to be reached in a lower
percentage of healthy HIV-infected patients.
Further study of this phenomenon in humans is warranted. This data validates the
pursuit of a large clinical trial to examine the immunosuppressive effects of concurrent
ZDV and SMX-TMP therapy. In addition to a larger sample size and patient
randomization, the use of normal healthy volunteers would be useful. This would isolate
the effects of the drug combination, eliminating the confounding factors that are
associated with HIV-infected patients, including affects of other medications (especially
PI, which can decrease ZDV-induced apoptosis), variable CD4+ counts and function,
and direct effects of viral immunosuppression. The analysis of serial antibody titers
would also be beneficial, because the differences we observed at a single point postvaccination could be only a reflection of altered timing of the response. In addition, a
vaccine to which the subjects were naïve (unlike influenza in most cases) would be
more ideal, such as Haemophilus b vaccine.

Clinical experience with SMX-TMP

Despite the fact that the clinical significance of this drug-drug interaction is unknown,
experience dictates that SMX-TMP must be discontinued in patients due to decreases
in overall white blood cells counts. There is a subset of newly-diagnosed patients that,
after beginning HAART, have viral loads that proceed to undetectable levels, but that do
not have CD4+ T cell counts rebound to safe numbers as usually seen (271). In one
study, 17% of patients have a dissociation between viral load reduction to undetectable
levels and a complete restoration (>50 cells/μl) after 6 months of HAART (271). Formal
investigation of whether discontinuation of SMX-TMP in these patients improves CD4+ T
cell numbers has not been conducted.
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E. CONCLUSIONS

We conclude that clinicians should consider this drug-drug interaction when treating
patients with ZDV and SMX-TMP concurrently. Our findings demonstrate that the host
response to infectious challenge is altered in mice and humans having received these
agents in combination. This suppression of humoral immunity could affect morbidity
and mortality of patients infected with HIV who receive both of these agents. This
iatrogenic effect, if clinically significant, could have an impact on outcomes to other
opportunistic and true pathogens that afflict this patient population. Additional
antiretrovirals are available which cause much less bone marrow toxicity than ZDV, and
patients at high risk of bone marrow suppression could potentially benefit from
alternative agents in the treatment of their chronic HIV infection. Likewise, clinicians
may wish to consider alternatives to SMX-TMP for the treatment and prophylaxis of
PCP (such as TMP alone or aerosolized pentamadine) in specific patients.

Copyright © David James Feola 2005
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